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ABSTRACT 
This dissertation is an effort to further define sites and cellular mechanisms of action 
of exogenous and endogenous GH secretagogues (GHS). The enclosed experiments have 
been performed on porcine somatotropes using an in vitro approach. 
The first study looked at the ability of benzolactam GHS - L-692,585 (L-585) to 
stimulate Ca2+ transients and GH secretion from cultured porcine somatotropes. Perfusion 
application of L-585 dose dependency increased intracellular calcium ([Ca2+];) in 
somatotropes. With concurrent reverse hemolytic plaque assay (RHPA) and [Ca2+]; 
measurements, it was shown that the increase in [Ca2+]j evoked by L-585 coincides with GH 
secretion. Incubation of cultured cells with L-585 increased the number and size of plaques 
around somatotropes, showing a stimulatory effect of L-585 on GH secretion. 
The second study using atomic force microscopy demonstrated for the first time the 
presence of the fusion pores at the plasma membrane of isolated porcine somatotropes. In the 
resting somatotropes were found 'pits' containing several 'depressions', or fusion pores, with 
diameter of 100-200 nm. After stimulation of secretion with L-585 'depressions' enlargement 
for about 40 % was observed. That 'depressions' are structures at plasma membrane of 
somatotropes involved in hormone secretion was confirmed by using gold-tagged GH-
antibody. This study together with previous studies on pancreatic acinar cells suggests that 
fusion pores may be common structures for all secretory cells, and that they are the sites 
where following stimulation membrane-bound secretory vesicles transiently dock and fuse to 
release vesicular content. 
The third study investigated the effects of an endogenous GHS - ghrelin on [Ca2+]j in 
cultured porcine somatotropes. The application of ghrelin resulted with changes in [Ca2+]; 
similar to those induced by L-585. Our experiments have shown that rapid increase in [Ca2+]i 
induced both by L-585 and ghrelin originated from the intracellular stores, while the plateau 
phase resulted from somatotropes depolarization and extracellular calcium entry. 
Simultaneous application or application in succession of L-585 and ghrelin has revealed 
antagonistic effects between these two agonists that may result from competition at the 
receptor level and/or downstream from GHS-R. 
Collectively, the results from these studies indicate that stimulatory effect of ghrelin 
and synthetic GHS on [Ca2+]j in cultured porcine somatotropes closely parallel each other, in 
a manner that is consistent with an increase of GH secretion. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Neuroendocrine regulation of growth hormone (GH) secretion primarily involves 
reciprocal interactions between GH-releasing hormone (GHRH) and somatostatin (SS), 
exerting both stimulatory and inhibitory influences, respectively, on somatotropes. GH also 
participates in its own rhythmic secretion through feedback action on GHRH- and SS-
neurons (Chan et al. 1996a). 
A group of peptide and non-peptide mimetics, termed GH secretagogues (GHS), 
stimulate GH secretion via a mechanism distinct from GH-releasing hormone (GHRH) 
(Smith et al. 1996a, 1997). A receptor for GHS (GHS-R) was cloned from the pituitary of 
several species (Howard et al. 1996, McKee et al. 1997), and an initial mapping study 
identified numerous sites of expression of GHS-R in several hypothalamic nuclei, as well as 
in other brain structures (Guan et al. 1997). Recent cloning of ghrelin (Kojima et al. 1999), 
an endogenous ligand for GHS-R, has revealed that the GHS system is probably an additional 
physiological regulator of GH secretion, and it is likely to have global peripheral and central 
effects. 
The focus of this dissertation is to elucidate site(s) and cellular mechanism(s) of 
action of GHS [ghrelin and L-692,585 (L-585)] on porcine somatotropes using an in vitro 
approach. 
The effects of ghrelin and L-585 on GH release, changes in intracellular calcium 
(A[Ca2+]j) and membrane structure associated with secretion in somatotropes were observed. 
This study is important for understanding the role of GH secretagogues in nutrient 
partitioning. Knowledge of the mechanisms by which ghrelin and other specific GHS 
stimulate GH secretion may ultimately be applied to management, nutrition and/or 
breeding/genetics approaches that optimize GH secretion. An understanding of mechanisms 
by which non-peptidyl GHS modulate GH secretion may be particularly significant because 
of their efficacy of oral administration, and possible clinical application. 
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Dissertation organization 
This dissertation is composed of three journal papers. In the first and the third paper, 
the effects of L-585 and ghrelin on cultured porcine somatotropes were observed. All of the 
experimental and research work presented in these two papers was carried out by myself and 
under the guidance of Dr. Srdija Jeftinija and Dr. Lloyd L. Anderson. The first paper 
(Chapter 2) has been published in Journal of Endocrinology (175:625-636) and all material is 
reproduced by permission of the Society for Endocrinology. The second paper describes 
structure and dynamics of fusion pores in cultured porcine somatotropes. In that paper I am 
one of co-authors. I have cultured porcine pituitary cells, treated them with nonpetidyl GH 
secretagogue-L-585, and analyzed GH secretion stimulated by L-585 using reverse hemolytic 
plaque assay (RHPA), while atomic force microscopy (AFM) was done by our collaborators 
from Dr. Jena's laboratory. The second paper (Chapter 3) has been published in 
Endocrinology (143:1144-1148) and all material is reproduced by permission of publisher. 
Each journal paper compromises a single chapter of the dissertation. The papers are 
preceded by a general introduction chapter containing a literature review, and followed by a 
general conclusion chapter consisting of a general discussion section and summary. The 
references are listed at the end of the chapter in which they are cited. 
Literature review 
Growth hormone 
Growth hormone (GH), also called somatotropin, is polypeptide hormone synthesized 
and secreted by specific cells - somatotropes, of the anterior pituitary gland. Somatotropes 
are located mainly in two lateral wings of the anterior lobe. Those cells are usually medium 
size and spherical or oval, with a spherical, centrally located nucleus and with well-developed 
cytoplasm showing low electron density and containing slim rough endoplasmic reticulum 
cistemae and a conspicuous Golgi complex (Kovacs & Horvath 1985). 
GH is an anabolic hormone responsible for postnatal growth, weight gain, and whole 
body nitrogen retention (Strobl & Thomas 1994). It causes growth of almost all tissues by 
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affecting protein, lipid and carbohydrate metabolism, cell multiplication and cell 
differentiation. Most of these growth effects of GH are achieved indirectly by stimulating 
production of small proteins called somatomedins that stimulate growth of bones and other 
tissues (Guyton 1991). Furthermore, there are some indications that GH also may be involved 
in regulation of sleep, reproduction, immune function, mental well being, and the aging 
process (Strobl & Thomas 1994). 
Synthesis and release of GH are controlled by a number of factors, including 
hypothalamic and glandular hormones. GH is normally released from somatotropes in a 
circadian, pulsatile fashion; however, the basis of the pulsatile release of GH still remains 
unknown (Muller et al. 1999). Also unknown is whether the complex episodic pattern of GH 
secretion determines the effectiveness of GH on its target tissues. Studies using separate 
injection or infusion patterns confirmed that skeletal growth in rats is dependent on pulse 
frequency as well as amplitude for GH (Jansson et al. 1982, Clark et al. 1985), but 
continuous GH was much more effective than daily injections in reducing fat stores (Clark et 
al. 1996). The GH secretory pattern is sexually dimorphic (Eden 1979, Jansson et al. 1985). 
Sex-related differences in GH secretion patterns have been studied extensively in rats. Male 
rats exibit low basal GH levels associated with the high amplitude and regular frequency 
pulses (Tannenbaub & Martin 1976), while female rats in contrast maintain elevated basal 
GH levels with irregular low amplitude pulses (Eden 1979, Clark et al. 1987). These 
differences are attributed to modulation of hypothalamic function by gonadal factors and 
higher levels of GH-releasing hormone (GHRH) and somatostatin (SS) expression in males 
as compared to females (Jansson et al. 1987, Argente et al. 1991, Lago et al. 1996). Sex 
differences in the pattern of GH secretion are not so clear-cut in humans, but there is a 
noticeably higher serum GH concentration in women than in men (Winer et al. 1990, 
Chapman et al. 1994). In addition to being sex-dependent, the pattern of spontaneous GH 
release is also age-dependent (Eden 1979, Ho et al. 1987, Kamegai et al. 1999). In all 
mammalian species studied to date, circulating GH concentrations are elevated during the 
perinatal period and then decline progressively to the time of weaning (Rieutort 1974, 
Strosser & Mialhe 1975). A secondary rise in circulating GH concentrations occurs during 
sexual maturation in both males and females, and at this time the pattern of GH secretion 
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becomes gender specific as result of hypothalamic function modification by gonadal factors 
(Strosser & Mialhe 1975, Muller et al. 1999). The decrease in GH serum concentration with 
aging very likely results from decreased pituitary secretion, secondary to enhanced insulin­
like growth factor-I (IGF-I) hypothalamo-pituitary feedback, or to changes in the pituitary 
sensitivity to SS and GHRH (Muller et al. 1999). In rats, the decrease in circulating GH 
concentrations was observed from dl to d20 and it was associated with an increase in 
pituitary responsiveness to SS (Oliver et al. 1982, Torronteras et al. 1997). In addition, 
juvenile and adult pituitaries are less sensitive to the stimulatory action of GHRH (Szabo et 
al. 1986, Shulman et al. 1987), that has been linked to decrease in GHRH receptor synthesis 
(Korytko et al. 1996, Kamegai et al. 1999). 
Mechanism of GH secretion 
Pituitary cells have a regulated pathway utilized by secretory vesicles that fuse with 
the plasma membrane. Secretory granules of the endocrine cells store and release peptide 
hormones and are the counterpart of neuronal large dense-core vesicles (Jahn & De Camilli 
1991). Translucent vesicles of pituitary cells are designated as synaptic-like microvesicles 
because of their similar appearance, molecular constituents and exoendocytotic recycling to 
synaptic vesicles. Synaptic proteins have been shown to be essential for the life cycle and 
exocytosis of synaptic vesicles at the nerve terminal. Purification of N-ethylmaleimide-
sensitive fusion protein (NSF) and soluble NSF attachment proteins (SNAPs) initiated the 
search for the mechanism of vesicular transport and release (Sollner et al. 1993a,b). An 
affinity purification procedure based on the natural binding of NSF and SNAPs to their 
targets was used to isolate SNAP receptors (SNAREs). Recently, synaptic proteins including 
Rab3a, synaptotagmin, syntaxin 1, SNAP-25, synaptophysin, and synaptobrevin isoforms 
(synaptobrevin 2 and cellubrevin) were found in pituitary cells (Redecker et al. 1995, 
Jacobsson & Meister 1996, Majo et al. 1998). These results suggest similar secretory 
mechanisms for synaptic vesicles and secretory organelles in both neuronal cells and pituitary 
cells, including somatotropes. 
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Regulation of GH secretion 
The regulation of GH secretion has been the focus of research since Reichlin in 1960 
observed that in rat surgical destruction of the ventromedial hypothalamus slows growth 
velocity (Reichlin 1960). First, at the end of 1960s and during 1970s GH release inhibiting 
hormone or somatostatin was discovered (Brazeau et al. 1973). About 10 years later GH-
releasing factor was identified and sequenced (Zafar et al. 1979, Rivier et al. 1982). A dual 
complex interplay between these two hypothalamic factors has a primary role in the 
regulation of GH secretion from anterior pituitary (AP) gland in mammals. GHRH, 
stimulates GH synthesis and release, and somatotrope proliferation, while SS, through its 
inhibitory influences modulates GH release and regulates GH pulsatility (Muller et al. 1999). 
GHRH- and SS-containing neurons, reside primarily in the hypothalamic arcuate nucleus 
(ARC) and the periventricular nucleus (PVN), respectively (Muller et al. 1999). The presence 
of the SS axons and perikarya also in ARC and ventromedial nucleus (VMN), two areas from 
which GHRH neurons originate, indicate the existence of an anatomic and functional peptide 
interaction (Liposits et al. 1988). The concept that GHRH and SS interact within CNS to 
modulate GH secretion is further suggested by colocalization of S S receptors and GHRH 
producing cells within the ARC (Bertherat et al. 1992). According to the general model 
proposed by Tannenbaum and Ling (1984) GHRH release during troughs in sinusoidal 
pattern of S S release induces the episodic release of GH, and the rise in S S suppresses 
baseline release. Evidence has accumulated that this traditional modest model has to be 
expanded to include other hypothalamic and peripheral factors that can be involved in 
regulation of GH secretion. 
GH feeds back on the hypothalamus to regulate its own secretion. The feedback 
regulation of GH presumably involves either activation of S S or inhibition of GHRH (Chan 
et al. 1996a). It seems that neuropeptide Y (NPY) and galanin are involved in feedback 
control of GH (Chan et al. 1996a,b). Beside short loop effects of GH on the hypothalamic 
neurons, long-loop feedback regulation of GH secretion might be operated by IGF-I, 
nonesterified fatty acids (NEFA) and glucose (Muller et al. 1999). In addition, GHRH and SS 
neurons are subject to modulation by complex network of neurotransmitters, especially 
noradrenergic and cholinergic, and other hypothalamic peptides, and they are likely the final 
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mediators of metabolic, endocrine, neural and immune influences for GH secretion (Muller et 
al. 1999; Table 1). 
Table 1 Neurotransmiters and growth hormone secretion: 
Subjects Animals Humans 
Epinephrine (E) t  | a,b 
CCi \ t  +? 
a2 t  t  
P. t c  + 
P2 \ 1 
Norepinephrine (NE) t  t  
Dopamine (DA) t  t  \  
5 -hy droxytryptamine (5-HT) t  V t  1? 
5-HT, t  « t  '  
5-HT2 À A 
Acetylcholine (ACh) t  8  À t  
g  
Histamine (H) t  
— 
H, 4 t  
A 
H2 J,  t  
y-Amino butyric acid (GABA) t  \  t  
Glutamate t h  
, Stimulation; :, slight stimulation; , inhibition; , no effect; -, action not ascertained; 
?, action still questionable.a In combination with propranolol;b inhibitory in acromegaly and 
in vitro anterior pituitary;c in vitro\ d inhibition in dog; e 5-HTlc subtype;f 5-HTm subtype;g 
muscarinic receptors; h iV-methyl-D-aspartate (NMDA) and non-NMDA receptors (modified 
from Muller et al. 1999). 
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The discover of family of GH-secretagogues (GHS), which includes GH-releasing 
peptides (GHRP), and non-peptidergic mimetics, that stimulate GH release both in vivo and 
in vitro in several species, suggest that beside GHRH and SS, the third component may play 
relevant role in GH secretion (Bowers 1996, Smith et al. 1996a). Although the exact 
mechanism of action of GHS has not been fully established, they probably act on both the 
pituitary and hypothalamus (Dickson et al. 1995, Casanueva & Dieguez 1999). It is proposed 
that exogenous GHS may involve regulatory factors in addition to GHRH and SS, and induce 
the release of another hypothalamic factor with GH-releasing capabilities designated as U-
factor (Bowers et al. 1991, Casanueva & Dieguez 1999). Cloning of specific GHS receptors 
(GHS-R) (Howard et al. 1996), and the isolation and characterization of an endogenous 
ligand for GHS-R, named ghrelin (Kojima et al. 1999), implicates GHS as a new 
physiological system in growth regulation (Tschop et al. 2000, Nakazato et al. 2001). 
GH- secretagogues and GH- secretagogues receptor 
In the late 1970s and early 1980s, the field of GHS research grew out of studies 
conducted on opoid peptides. After finding that some opioid peptide derivatives had weak 
GH-releasing activity, in search for more potent GHS Bowers and coworkers tested the GH 
releasing properties of many peptides, derived from structural modification of Leu- and Met-
enkephalin. The data obtained from complex conformational energy calculations were used 
to relate structural features to the tasted GH-releasing capabilities. Subsequent substitutions 
of amino acids with specific chemical properties at the selected positions of peptide have 
improved binding and intrinsic activity of these compounds (Bowers et al. 1980, 1984, 
Momany et al. 1984). This approach resulted in 1980 with the discovery of the first highly 
potent GH-releasing hexapeptide named GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; 
Fig.l) (Bowers et al. 1984). GHRP-6 released GH both in vitro and in vivo, and it was active 
in several animal species and in humans (Bowers et al. 1984, Ilson et al. 1989). Since the 
discovery of GHRP-6 a range of GH-releasing peptides has been developed with varying 
potency, including hexapeptides hexarelin and GHRP-2, heptapeptide GHRP-1, octapeptide 
Tyr-Ala-hexarelin as well as penta-, tetra-, pseudotripeptides and some cyclic peptides 
(Camanni et al. 1998, Casanueva & Dieguez 1999). 
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His - DTrp - Ala - Trp - oPhe - Lys - NH2 
NH 
CHj 
.NH, .NH, NH 
NH NH NH. 
HN HN 
NH, 
*=(CH3)-hexarelin 
GHRP-6 
,N—C-CHz—C-NHz 
N=N 
.NH 
L-692,429 
,N—C-CH2—C-NH—CHjCHCH3 
N=sN 
NH 
L-692,585 
MK-0677 
Figure 1 Structures of peptidyl and nonpeptidyl GH secretagogues (modified from Smith et 
al. 1993 and Casanueva & Dieguez 1999). 
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Although GHRP were based on an opioid peptide, they were devoid of opioid activity 
and it was shown that GHRP effectively release GH in animal and man after intravenous, 
subcutaneous, intranasal, and even oral administration (Camanni et al. 1998). Because of the 
limited oral bioavailability of GHRP, Merck researchers in 1988 embarked on a research 
program to discover a nonpeptidyl mimic of GHRP-6 with improved oral bioavailability and 
pharmacokinetics properties (Smith et al. 1993, 1996a, 1997). Benzolactam L-692,429 
(Fig.l) was the first identified selective nonpeptide GH secretagogue (Smith et al. 1993). The 
in vivo specificity of L-692,429 was first evaluated in beagles (Smith et al. 1993), and 
subsequently in human studies (Gertz et al. 1993). In common with GHRP-6 (Huhn et al. 
1993), constant infusion of L-692,429 for 24 h in man provided pulsatile GH release 
(Chapman et al. 1996). Low oral availability of L-692,429 in animal models and modest 
potency in humans initiated detailed investigation of the structure-activity relationships for 
benzolactams. The basic amine in the benzolactam class of secretagogues was shown to be 
critical for GH releasing activity and series of amino substituents were designed to modulate 
basicity and lipophilicity (Wyvratt 1996). L-692,585 (L-585; Fig. 1), a 2-hydroxypropyl 
analogue of L-692,429, was found to be approximately 20-fold more potent than L-692,429 
in the rat pituitary assays (Schoen et al., 1994), and in beagles in vivo (Jacks et al. 1994). 
Infusion of L-585 into guinea pigs was shown to initiate and amplify pulsatile GH release 
(Fairhall et al. 1995). The spiroindoline MK0677 (Fig. 1) was another nonpetidyl 
secretagogue evolved through structural modification and sought for orally active molecules 
more suitable for chronic use. Oral bioavailability of MK0677 has been >60 %, that was 
much bigger comparing to 2 % and 1% oral bioavailability of L-692,429 and GHRP-6, 
respectively (Smith et al. 1996b). Chronic oral treatment of dogs once daily with MK0677 
initiated an amplified pulsatile pattern of GH release, and it was proposed that this class of 
secretagogue may indeed mimic an endogenous hormone responsible for pulsatile GH release 
(Smith et al. 1996b). 
It became clear from early studies that the GHS elicited their effects on GH secretion 
through receptors and signaling pathways distinct from that of endogenous GHRH (Wu et al. 
1996). This conclusion was made based on findings that GHRH receptor antagonist inhibited 
GHRH-stimulated GH release but not GHS-stimulated GH release (Wu et al. 1996), and 
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putative GHS-R antagonist did not affect GH release in response to GHRH (Cheng et al. 
1989). In addition, GHRH and GHS had synergistic or additive effect on GH release when 
they were coadministered, and there was no cross-desensitization between GHRH and GHS 
in terms of GH release, whereas homologue desensitization occurred (Wu et al. 1994a,b, 
Bowers 1996). The synergistic GH response supported an independent and complementary 
relationship of GHRH and GHS. 
The GHS-R was cloned and characterized in several species and it was shown that 
this receptor mediates the activity of GHRP and nonpeptidyl ligands, (Howard et al. 1996, 
Smith et al. 1996b, McKee et al. 1997). The identification of the GHS-R confirmed that GHS 
indeed form part of an alternative physiological system for the regulation of GH secretion, in 
addition to GHRH and SS. Molecular analysis has shown that cDNA encoding GHS-R is 
highly conserved among various mammalian species, including human, chimpanzee, swine, 
bovine, rat and mouse (Howard et al. 1996, Mitchell et al. 2001). The GHS-R was found to 
be classical G-protein coupled receptor, containing seven putative alpha-helical membrane 
spanning segments and three intracellular and extracellular loops. This receptor appears to be 
the first of a new family of G-protein-coupled receptors, since it does not show significant 
functional homology with any other proteins and receptor known so far (Howard et al. 1996). 
Its closest relatives are neurotensin and motilin receptors with 35 % and 52 % protein 
sequence identity (Howard et al. 1996, Feighner et al. 1999). 
To date two different subtypes of GHS-R have been described, types la and lb. In 
humans and swine the GHS-R subtype la (Fig. 2) is a functional, 366 amino acid 
polypeptyde with seven transmembrane (TM) domains (Howard et al. 1996). The rat GHS-R 
type la is also 7 TM receptor, but compared with the human and swine GHS-R is two amino 
acids shorter, with a loss of one residue each in the amino-terminal extracellular domain and 
the third intracellular loop (McKee et al. 1997). The subtype lb is a truncated version of 
GHS-R with only 5 TM domains and with no measurable functional activity in cell-based 
assays (Howard et al. 1996, McKee et al. 1997). 
The GHS-R are mainly present at the pituitary and hypothalamic level but also in 
other areas of the central nervous system (CNS), such as the cerebral cortex, hippocampus, 
medulla oblongata and choroid plexus (Howard et al. 1996, Muccioli et al. 1998). The 
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existence of GHS-R at the pituitary level and within the CNS explains the neuroendocrine 
and extraneuroendocrine activities of GHS, such as the control of sleep and food intake 
(Frieboes et al. 1995, Locke et al. 1995). GHS-R are also present at the peripheral level in 
both endocrine and nonendocrine tissues (Papotti et al. 2000), but their functional 
significance is still unknown. Recent findings suggest that at least in cardiovascular system 
and thyroid gland GHS-R could mediate GH-independent GHS activities (Ghigo et al. 2001). 
Three 
extracellular 
loops 
Seven 
transmembrane 
domains 
Three 
intracellular 
loops 
0 0 0  J % @  3 0  O O O  
®A W> 
fee© î>®0 (5)0® 
O O O  O O O  
Figure 2 Predicted membrane topology and amino acid sequence of the human type 
la GHS-R (modified from Smith et al. 1997). 
All peptide and non-peptide ligand classes share a common binding domain in TM-3 
region of GHS-R, while contacts in other TM domains and extracellular loop 1 of the 
receptor reveal specificity for the different GHS (Feighner et al. 1998). Changes in 
intracellular Ca2+ concentration ([Ca2+];), cyclic adenosine monophosphate (cAMP), protein 
kinase A (PKA) and C (PKC), and phospholipase C (PLC) are possible signaling systems 
involved in the action of GHS (Smith et al. 1997, Muller et al. 1999, Chen 2000). The 
different signalling systems employed by different GHS in different animal species may 
reflect existence of more than one subtype of GHS-R (Chen 2000). 
12 
Mechanism of action of GHS still remains obscure. Although GHS selectively release 
GH by a direct pituitary action (Bowers et al. 1984, Cheng et al. 1989, Sânchez-Hormigo et 
al. 1998), there is good evidence that the GHS also act in the hypothalamus (Dickson et al. 
1993, Guillaume et al. 1994). Moreover, GHS require the presence of a functional 
hypothalamus to be fully operative (Pombo et al. 1995, Popovic et al. 1995). The exact 
pathways through which GHS act in the hypothalamus to release GH are not known. In the 
hypothalamus GHS-R la mRNA is expressed in neuropeptide Y (NPY)/agouti-related 
protein (AGRP), SS, GHRH and proopiomelanocortin (POMC) neurons (Tannenbaum et al. 
1998, Willesen et al. 1999). It has been reported that GHS induce c-fos expression, a marker 
of neuronal activity, mainly in NPY and GHRH neurons, but also in POMC and SS neurons 
(Kamegai et al. 1996, Dickson & Luckman 1997). Activation of GHRH neurons by GHS can 
be direct or indirect through activation of SS and/or NPY neurons (Bluet-Pajot et al. 2001). 
GHS do not appear to inhibit hypothalamic SS release (Guillaume et al. 1994, Korbonits & 
Grossman 1995, Fletcher et al. 1996). The issue of whether or not GHS act directly on 
GHRH neurons is still controversial. The increase in GHRH has been measured in 
hypothalamic-pituitary portal vessels of sheep after systemic treatment with GHRP 
(Guillaume et al. 1994), but GHRP did not stimulate GHRH release with perfusion of rat 
hypothalamus in vitro (Korbonits & Grossman 1995). It seems that GHS-elicited GH 
secretion is not mediated by changes in endogenous GHRH or SS, and it is proposed that 
GHS may induce the release of another hypothalamic factor with GH-releasing capabilities -
"U-factor" (Casanueva & Diguez 1999). 
Ghrelin 
The search for GHS-R endogenous ligand was actively undertaken in the last few 
years. In 1999, endogenous ligand for GHS-R was discovered by a Japanese research group 
(Kojima et al. 1999). The natural, endogenous ligand for GHS-R was always believed to be 
another hypothalamic peptide, but surprisingly it was isolated from both the rat and the 
human stomach. The Japanese research group used a Chinese hamster ovary (CHO) cell line 
that express GHS-R to monitor changes in [Ca2+]; and by screening extracts from several 
tissues, it was observed that the highest level of GHS-R activation occurs in response to 
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stomach extract. The purified ligand was named ghrelin. "Ghre" is the Proto-Indo-European 
root for the word growth and the suffix "relin" signifies that this peptide stimulates GH 
release (Kojima et al. 1999). 
Ghrelin is relatively charged linear, non-C-terminal amidated 28 amino acids peptide 
(Fig. 3) with a significant number of functional groups. The third serine residue in ghrelin is 
w-octanoylated, and this posttranslation modification by an acyl acid is unique among 
mammalian bioactive peptides. The n-octanoyl group adds hydrophobic property to the N-
terminus that may facilitate entry and distribution in the brain. Without octanoylation, ghrelin 
is biologically inactive (Kojima et al. 1999, Bednarek et al. 2000). Interestingly, it was 
shown that the first four to five residues of ghrelin activate GHS-R as efficiently as a full 
length of ghrelin (Bednarek et al. 2000). The cDNAs for rat, mouse, dog and human ghrelin 
have been cloned (Kojima et al. 1999, Tanaka et al. 2001, Tomasetto et al. 2001). The 
structure of ghrelin is highly preserved among different species, and human ghrelin differs 
from rat ghrelin in two residues (Kojima et al. 1999). Sequence comparison indicated that 
ghrelin and motilin share partial homology. Human ghrelin and human motilin have 36% 
identity, and GHS-R show a remarkable overlap with motilin receptor (Asakawa et al. 2001). 
These facts suggest that ghrelin and motilin might have evolved from a common ancestral 
peptide. 
O= c- (CH2)6 CH3 
o 
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Figure 3 Structure of rat ghrelin (modified from Kojima et al. 1999). 
Following the discovery of ghrelin, a second endogenous ligand for GHS-R was also 
isolated from the rat stomach (Hosoda et al. 2000). This peptide was identical to ghrelin, 
except for the deletion of Gin 14, and it was called des-Gln 14 ghrelin. Des-Gln 14 ghrelin is 
encoded by a mRNA created by alternative splicing of the ghrelin gene. The activity of both 
ghrelins is the same. However, des-Gln 14 ghrelin is only present in low amounts in the 
stomach, indicating that ghrelin is the major active form (Kojima et al. 2001). 
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Ghrelin mRNA, as was shown by northern blot analysis, is primarily expressed in the 
mucosal layer of the stomach with concentrations decreasing distally along the intestine 
(Kojima et al. 1999, Date et al. 2000). Date et al. (2000) demonstrated that stomach ghrelin is 
present in distinct cell type, X/A like endocrine cells of submucosal layer, or now designated 
as ghrelin cells. These cells contain round, compact electron-dense granules and are field 
with ghrelin. The ghrelin cells are not in continuity with the stomach lumen, but rather are 
closely associated with the capillary network of the lamina propria, suggesting that ghrelin is 
secreted into the blood vessels (Kojima et al. 2001). 
Ghrelin expression is not restricted to the gastrointestinal tract, but it is also produced 
in the pancreas, kidney liver, immune cells, pituitary and hypothalamus (Kojima et al. 1999, 
Mori et al. 2000, Hattori et al. 2001, Korbonits et al. 2001). Ghrelin was also found in rat and 
human placenta (Gualillo et al. 2001), suggesting that ghrelin-GH axis might be active early 
in development. 
Ghrelin receptors (GHS-R) also have widespread distribution in the peripheral tissues. 
The presence of these receptors was documented in the pituitary, hypothalamus, stomach, 
heart, blood vessels, lung, pancreas, intestine, kidney, adipose tissue, immune system and in 
human breast carcinomas (Wang et al. 2002). The expression of ghrelin and its receptors in 
these various tissues suggests multiple paracrine, autocrine and endocrine, physiological and 
pathophysiological roles for ghrelin. 
Base on the evidence that nonnatural GHS are the strong activators of the GH release, 
it was reasonable to expect that ghrelin, as an endogenous ligand for GHS-R, possesses GH -
releasing activity. In fact, it has been shown that ghrelin acts directly on the somatotropes, 
and in a dose dependent manner stimulates GH secretion from rat pituitary cells in culture. 
This stimulatory effect of ghrelin on GH secretion is specific, and does not affect other 
pituitary hormones, even at high ghrelin doses (Kojima et al. 1999). Furthermore, it was 
found that in rodents ghrelin, given systematically or into the brain (icv), stimulates GH 
secretion (Kojima et al. 1999, Date et al. 2000, Toile et al. 2001). After intravenous injection 
of ghrelin to rat, plasma GH levels peaked 5-10 min after injection, and returned to basal 
levels lh later (Toile et al. 2001). It has recently been shown that ghrelin in a dose dependent 
manner stimulates GH-release in humans (Takaya et al. 2000, Arvat et al. 2001, Hataya et al. 
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2001). In normal male adults, iv administration of ghrelin in doses of 0.2, 1 and 5 gg/kg 
induced prompt increase in circulating GH levels that reached peak values 30 min after 
injection. Adrenocorticotropin (ACTH), Cortisol and prolactin (PRL) levels were also 
elevated after ghrelin injection. At the low iv bolus dosage ghrelin induced only minimum 
peak values of these hormones, suggesting that at physiological concentrations, ghrelin 
possibly would not increase ACTH or PRL (Takaya et al. 2000, Arvat et al 2001). Ghrelin 
exhibited a similar time course for GH release to those of GHS (Takaya et al. 2000). The 
potency of ghrelin for GH release was similar to those of GHS, but much greater than 
GHRH, indicating a distinctive pharmacological action (Takaya et al. 2000, Arvat et al. 
2001). At small dose ghrelin synergised with GHRH on GH secretion, that also suggested 
different sites of action for these hormones (Arvat et al. 2001, Hataya et al. 2001). On the 
other hand, several studies have shown commonality of action of GHRP and ghrelin. The 
endocrine responses to ghrelin were not modified by the coadministration of hexarelin, a 
nonnatural peptidyl GHS (Arvat et al. 2001). In experiments with repeated administration of 
ghrelin or GHRP-2, desensitization of the GH response was induced homologously and also 
heterologously in crossover studies. Also, combined ghrelin and GHRP-2 at maximal 
dosages induced the same magnitude of GH release as when the peptides were administrated 
alone (Bowers 2001). Together, these in vivo assays confirmed that ghrelin is a new hormone 
playing an important role in GH secretion. Still is unknown whether ghrelin itself stimulates 
pituitary GH synthesis either directly or indirectly via the release and/or augmentation of the 
pituitary action of GHRH and other hypothalamic factors. 
A large number of animal and human studies have shown that in addition to role in 
regulation of GH secretion, ghrelin is involved in the regulation of energy balance. The 
positive energy balance induced by ghrelin seems to be necessary to maximize the anabolic 
actions of GH (Inui 2001). Ghrelin has a complex function in growth regulation by both 
stimulating GH secretion, and by stimulating feeding. Adipogenic as well as orexigenic 
effects of ghrelin are independent from its ability to stimulate GH secretion. It was shown 
that ghrelin increases feeding in rats that are genetically deficient in GH (Nakazato et al. 
2001). 
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In rodents, ghrelin can stimulate food intake when given either systemically or icv 
(Asakawa et al. 2001, Nakazato et al. 2001). The central injection of ghrelin produced more 
robust and sustained food intake, indicating a central mode of action (Tschop et al. 2000). 
Fasting and hypoglycemia increased ghrelin levels, whereas intake of food, especially 
carbohydrates, decreased ghrelin secretion (Tschop et al. 2000, Asakawa et al. 2001, 
Nakazato et al. 2001). 
The orexigenic effect of ghrelin was also observed in humans (Arvat et al. 2001). In 
humans, circulating ghrelin levels were decreased in obesity (Tschop et al., 20016) and acute 
feeding states (Tschop et al. 2001a), whereas plasma levels of ghrelin were increased by 
fasting (Cummings et al. 2001). Recently, pre-meal rise of human ghrelin was observed, 
suggesting a possible role of ghrelin as hunger signal triggering meal initiation (Cummings et 
al. 2001). 
The orexigenic activity of ghrelin is most likely mediated by its action on the arcuate 
nucleus of the hypothalamus. The arcuate nucleus is a major hypothalamic site for regulation 
of feeding behaviour and body weight since it harbors NPY, agouti-related peptide (AGRP), 
cocaine and amphetamine-regulated transcript (CART), and proopiomelanocortin (POMC) 
(Woods et al. 1998, Abbott et al. 2001). NPY and AGRP are orexigenic, whereas CART and 
POMC are anorexic peptides. GHS-R mRNA has been found in the hypothalamus, and 
immunohistochemical analyses indicated that ghrelin-containing cells are localized in the 
arcuate nucleus (Kojima et al. 1999). It is also possible that the fatty acid moiety facilitates 
passage across the blood-brain barrier, resulting in hypothalamic actions of systemic ghrelin 
(Inui 2001). After intracerebroventricular administration of ghrelin, Fos protein, a marker of 
neuronal activation, was robust in regions involved in regulation of feeding, including NPY 
and AGRP neurons (Kojima et al.  2001, Nakazato et al.  2001). It  was also shown that Yl-
receptor antagonists as well as melanocortin agonist and antisera to both NPY and AGRP 
might interfere with ghrelin's feeding-inducing effect (Asakawa et al. 2001, Nakazato et al. 
2001). However, the effect of ghrelin on feeding and adiposity was not diminished in NPY 
lacking mice, indicating a crucial role of AGRP in the mediation of ghrelin's effects on 
energy balance (Tschop et al. 2002). The effect of ghrelin on metabolism seems to be exact 
opposite to the leptin. Leptin is an adipocyte-derived blood-born satiety factor that acts 
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directly on the hypothalamus, where it regulates a large number of molecules implicated in 
energy homeostasis. Administration of leptin either centrally or peripherally inhibits appetite 
and adiposity and augments energy expenditure (Friedman & Halaas 1998). Seemingly, these 
opposing effects of leptin and ghrelin on appetite are mediated by NPY, AGRP and y-
aminobuteric acid (Horvath et al. 2001, Nakazato et al. 2001, Shintani et al. 2001). The exact 
mechanism of the interaction between leptin and ghrelin remain to be elucidated in the future 
studies. It is important to clarify the role of gastric ghrelin and the NPY/AGRP pathway in 
the pathogenesis of diet-induced obesity, because obesity and related disorders are among the 
leading causes of illness and mortality in the developed world (Mokdad et al. 2000). 
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CHAPTER 2. MECHANISM OF ACTION OF GROWTH HORMONE 
SECRETAGOGUE, L-692,585, ON ISOLATED PORCINE 
SOMATOTROPES 
A paper published in the Journal of Endocrinology (2002) 
Aleksandra Glavaski-Joksimovic, Ksenija Jeftinija, Aleksandar Jeremic, Lloyd L. Anderson, 
and Srdija Jeftinija 
Abstract 
The effects of a growth hormone (GH)-secretagogue, L-692,585 (L-585), and human growth 
hormone releasing hormone (hGHRH) on calcium transient and GH release were investigated 
in isolated porcine pituitary cells using calcium imaging and the reverse hemolytic plaque 
assay (RHPA). Somatotropes were functionally identified by application of hGHRH. All 
cells that responded to hGHRH responded to L-585 application. Perfusion application of 10 
|j,M hGHRH and L-585 for 2 min resulted in an increase in [Ca2+], of 53 ± 1 nM (mean ± 
SEM) (P < 0.01) and 68 ± 2 nM (P < 0.01), respectively. The L-585 response was 
characterized by an initial increase in [Ca2+]; followed by decline to a plateau level above the 
baseline. Concurrent calcium imaging with RHP A indicated that the L-585-evoked increase 
in [Ca2+]j coincided with GH release. L-585 significantly increased the percentage of plaque 
forming cells (24 ± 3 vs 40 ± 6 %; P < 0.05) and mean area of plaques (1,892 ± 177 vs 3,641 
+ 189 [am2; P < 0.01) indicating increased GH release. Substance P-analog ([D-Arg1, D-Phe5, 
D-Trp7 U]-SP) blocked, and the hGHRH receptor antagonist [(Phenylac-Tyr1, D-Arg2, p-
chloro-Phe6, Homoarg9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Homoarg29)-GRF (1-29) amide] 
decreased the stimulatory effect of hGHRH. These failed to block the stimulatory effect of L-
585 suggesting different receptor for L-585 from GHRH receptor. The hGHRH-induced 
calcium transients and initial peak increase induced by L-585 were significantly decreased by 
removal of calcium from bathing medium or the addition of nifedipine, a L-calcium channel 
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blocker. The plateau component of L-585-induced calcium change was abolished by removal 
of calcium and nifedipine. These results suggest an involvement of calcium channels in GH 
release. Either SQ-22536, an adenylyl cyclase (AC) inhibitor, or U73122, a phospholipase C 
(PLC) inhibitor, blocked the stimulatory effects of hGHRH and L-585 on [Ca2+]; transient 
indicating the involvement of AC-cAMP and PLC- IP3 pathways. These results further 
suggest calcium mobilization from internal stores during the first phase of the L-585 induced 
increase in [Ca2+]j whereas calcium influx during the second phase is a consequence of 
somatotrope depolarization. 
Introduction 
GROWTH HORMONE (GH) secretion is controlled by hypothalamic stimulatory- and 
inhibitory-releasing hormones, GH-releasing hormone (GHRH) and GH release-inhibiting 
hormone (GHRIH) or somatostatin (SS). GH also participates in its own rhythmic secretion 
through feedback action on GHRH and SS neurons (Chan et al. 1996). Pulsatile GH secretion 
can be stimulated and amplified by novel compounds known as growth hormone 
secretagogues (GHS) (Casanueva & Dieguez 1999). The mechanism of action of GHS is not 
fully established. GHS-elicited GH secretion involves both a direct effect and an indirect 
effect on the hypothalamus, suggesting that exogenous GHS may induce the release of 
another hypothalamic factor with GH-releasing capabilities (U-factor) (Bowers et al. 1991, 
Casanueva & Dieguez 1999). Cloning of the human GHS receptor (Howard et al. 1996) and 
the isolation and characterization of an endogenous GHS, designated as ghrelin (Kojima et 
al. 1999), implicates GHS as a new physiological system in growth regulation by stimulating 
feeding and release of GH (Nakazato et al. 2001). 
The growth hormone releasing peptides (GHRPs) were the first identified compounds 
in the class of GHS. Bowers and coworkers reported the discovery of a series of peptides 
derived from Leu- and Met-enkephalins that specifically released GH from the pituitary 
gland of animals and humans (Bowers et al. 1991). The biological action of GHRPs was 
considered different from GHRH. Benzolactam and spiroindolamine GHS have been 
developed with improved oral bioavailability and pharmacokinetic properties (Smith et al. 
1993, 1997); L-692,429 being the first described nonpeptidyl GHS (Smith et al. 1993). L-
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692,585 (L-585) is a nonpeptidyl GHS 10- to 20-fold more potent than L-692,429, as based 
on in vitro and in vivo studies and with no detectable change in receptor affinity (Jacks et al. 
1994, Schoen et al. 1994). The GHS activity of L-585 has been reported in several species 
including beagles (Jacks et al. 1994), sheep (Guillaume et al. 1994) and swine (Hickey et al. 
1996). In vivo experiments have shown that GHS in combination with GHRH augments GH 
release, and it is suggested that L-585 acts directly on somatotropes causing GH release 
(Smith et al. 1993). Besides direct effects on somatotropes, L-585 exerts central effects and 
requires an intact hypothalamic-pituitary axis for optimal GH release (Fairhhall et al. 1996, 
Hickey et al. 1996). Experiments in the pig in vivo have shown that L-585 also stimulates 
GH secretion by acting in combination with GHRH to interrupt the inhibitory tone of 
somatostatin (Hickey et al. 1996). 
The present studies examine the signal transduction mechanism of GHS, L-585 on 
calcium transient and GH release from isolated porcine somatotropes. An understanding of 
the molecular mechanisms by which GHS modulate GH secretion is of particular interest 
because of their biochemical simplicity and efficacy of oral administration. 
Materials and Methods 
Chemicals 
Fetal bovine serum (FBS), horse serum (HS), minimum essential medium (MEM), 
Dulbecco's modified Eagle's medium (DMEM), Earle's balanced salt solutions (EBSS) and 
guinea pig complement were purchased from Gibco-Invitrogen Co. (Carlsbad, CA, USA). 
HEPES, ethyleneglycol-bis-(|3-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), papain 
solution, trypsin-inhibitor, penicillin-streptomycin solution, poly-L-lysine, L-cysteine, L-
glutamine, sodium pyruvate, bovine serum albumin (BSA), nifedipine, and Staphylococcal 
protein-A were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Ovine red blood 
cells (oRBC) were purchased from Colorado Serum (Denver, CO, USA). Glucose, sodium 
bicarbonate (NaHC03), paraformaldehyde, and chromium chloride were obtained from Fisher 
Chemical (Fair Lawn, NJ, USA). Fura 2/AM and 4-bromo-A23187 were purchased from 
Molecular Probes (Eugene, OR, USA). ABC kit was obtained from Vector Laboratories 
(Burlingame, CA, USA). U73122 and SQ-22536 were purchased from Biomol Research 
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Laboratories (Plymouth Meeting, PA, USA). Somatostatin (SS), Substance P analog, (D-
Arg1, D-Phe5, D-Trp711)-SP, and GHRH antagonist, (Phenylac-Tyr1, D-Arg2, p-chloro-Phe6, 
Homoarg9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Homoarg29)-GRF (1-29) amide (human), were 
obtained from Bachem California, Inc. (Torrance, CA, USA). hGHRH and anti-porcine GH 
antibody were gifts from Dr A F Parlow, NIDDK National Hormone and Pituitary Program 
(Torrance, CA, USA). L-692,585 (L-585) was a gift from Dr G J Hickey, Merck Research 
Laboratories, Rahway, NJ, USA. 
Experimental animals 
Yorkshire pigs, raised at the Iowa State University Animal Nutrition Farm, were used for 
these experiments. Animal care and experimental protocols were in accordance with the 
guidelines and approval of the Iowa State University Committee on Animal Care. 
Preparation of cell cultures 
Newborn pigs, 1-8 days of age, were killed with electrical shock and decapitated. Pituitary 
glands were immediately removed. Total number of animals used was 32. The pituitary 
glands were collected in cold sterile BBSS solution (4 °C). Anterior lobes were transferred to 
a sterile cold (4 °C) MEM-0.1% BSA medium. Primary cell cultures from neonatal anterior 
pituitary gland were established using a modified method of Huettner & Baughman (1986). 
Tissues from two animals were incubated 50 min at 37 °C in 2 ml of EBSS-papain solution 
(1.54 mg/ml). After incubation, tissue was rinsed with BBSS solution and incubated for 5 
min in trypsin-inhibitor solution (1 mg/ml). After being rinsed, once with BBSS solution and 
once with DMEM-0.1% BSA medium, the tissue was mechanically dispersed in DMEM-
0.1% BSA medium by triturating through a firepolished glass pipette. The undigested tissue 
was allowed to sediment. The supernatant containing cells was removed and filtered through 
a sterile filter. Cells were plated onto poly-L-lysine (0.1 mg/ml; 100,000 kD) coated glass 
coverslips (at a density of 2 x 105 cells). Cells were allowed to attach to coverslips, and then 
after 3-4 h DMEM-0.1% BSA medium was exchanged with DMEM medium supplemented 
with 10% horse serum and 1 ml penicillin-streptomycin solution per 100 ml medium. 
Cultures were maintained at 37 °C in a humidified 5% C02/95% air atmosphere. Experiments 
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were carried out after 2 days in culture. The presence of somatotropes was confirmed by 
immunocytochemical methods. 
Immunocytochemistry staining 
After fixation with 4% paraformaldehyde for 30 min at room temperature, cells were 
incubated for 30 min in a 50% goat serum solution containing 1% BSA and 100 mM L-lysine 
to block nonspecific binding and 0.4 % Triton X-100 to permeabilize the membrane. To stain 
the somatotropes, cultures of anterior pituitary gland were incubated in polyclonal anti-
porcine GH antibody (dilution 1:50,000). Antibody visualization was accomplished by using 
a Vectastain ABC kit (Vector) and the nickel-enhanced 3-3' diaminobenzidine method 
(Jeftinija et al. 1992). 
Intracellular calcium imaging 
The effect of secretagogues on intracellular calcium concentration [Ca+2 ]; was evaluated by 
ratiometric imaging techniques (Parpura et al. 1994). Cells were loaded with Fura 2-AM for 
40-60 min at 37 °C. 1 jal of 25% (w/w) of Pluronic F-127 was mixed with 4 nM of AM ester 
to aid solubilization of the ester into aqueous medium. Coverslips containing pituitary cells 
were washed with HEPES-buffered solution and further incubated for 10 min at 37 °C to 
allow deesterification of Fura 2-AM. All image processing and analysis were performed 
using an Attoflour system with Zeiss microscope. Background subtraction and ratio images 
were used to calculate the [Ca+2]; according to Equation 5 of Grynkiewitz et al. (1985). Using 
wavelengths of 340 and 380 nm, Fura 2-AM was excited and the emitted light was collected 
at 520 nm. 
Reverse hemolytic plaque assay (RHPA) for measurement of GH release in culture mediu 
The RHPA was established according to the method of Taylor and Clark (Taylor & Clark 
1994). Staphylococcus protein A was coupled to ovine red blood cells using 0.1% CrCl3. 
After dissociation, pituitary cells were incubated for 48 h to allow them to recover biological 
responsiveness. After incubation, the cells were briefly exposed to trypsin (2.5 mg trypsin in 
10 ml MEM-0.1% BSA) to detach them from the culture dish. Following gentle triturating by 
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a firepolished glass pipette, the cells were separated by centrifugation (1,500 x g for 10 min), 
washed twice in MEM-0.1% BSA, and resuspended in DMEM-0.1% BSA. The working cell 
dilution was 2.5 x 105 cells/ml. Equal amounts of the single secretory cell suspension and a 
50% protein-A-labeled erythrocyte solution were mixed. The mixture was infused into 
Cunningham slide chambers and incubated at 37 °C in 95% air-5% C02 for 50 min. 
Pretreatment of the glass surface with poly-L-lysine (0.1 mg/ml; 100,000 kD) ensured 
anchorage of the cells. After incubation the chambers were rinsed with DMEM-0.1 % BSA. 
The monkey anti-porcine GH serum, diluted 1:60 in DMEM-0.1 % BSA, was then infused 
into the chambers alone or with L-585 (100 nM). The optimal incubation period was 
established by a preliminary study in which the maximum percentage of plaque-forming GH 
cells was achieved at 3 h. Plaque formation was initiated by infusion of guinea pig 
complement in a final dilution of 1:40 in DMEM-0.1 % BSA, and the reaction was 
terminated after 50 min by the infusion of 1% solution of glutaraldehyde. Omission of any of 
the assay reagents, i.e., antiserum, complement, protein-A, resulted in failure to form 
hemolytic plaque. 
In every experiment, each treatment (with secretagogue or vehicle) was run in 
triplicate. Three separate experiments were performed. On each slide, the percentage of 
plaque forming cells (% PFC) was determined by counting the number of plaques among 200 
pituitary cells. The mean plaque area (MPA) of 100 plaques/slide was measured by using a 
calibrated ocular reticule. The total secretion index, representing integrated hormone 
secretion per 100 pituitary cells, was calculated by multiplying the % PFC and MP A (Goth et 
al. 1992; Mitani et al. 1996). 
Combination of RHPA and measurement of [Ca'2]i 
A 1:1 mixture of protein-A-conj ugated ovine red blood cells and pituitary cells was incubated 
for 1 h in Cunningham slide chambers, and then loaded with Fura 2-AM for 40 min at 37 °C. 
Fura 2-AM was washed from the chamber with DMEM-0.1% BSA. Twenty minutes later the 
presence of pituitary cells was confirmed under the fluorescent microscope. Calcium 
measurements were performed using consecutive excitation at 340 and 380 nm. After 
recording a baseline of [Ca2+]; for 60 s, anti-porcine GH antibody and secretagogue (10 (a,M 
37 
L-585) were both introduced into the chamber. Changes in [Ca2+]; were monitored for 15 min. 
After recording, cells in the chambers remained on the microscope for 3 h. Complement was 
introduced into the chamber, leading to lysis of red blood cells adjacent to GH secreting 
pituitary cells. These plaques retrospectively identified the somatotropes. 
Statistical analysis 
Independent data are expressed as mean ± S.E.M. Simple comparisons between two groups 
were made by Student's t test. Multiple comparisons were carried out by one-way analysis of 
variance (ANOVA) followed by Tukey's Multiple Comparison Test. Differences were 
considered as statistically significant at P < 0.05. 
Results 
Morphological identification of somatotropes in culture 
Somatotropes in pituitary cell culture were confirmed by immunocytochemical staining. GH 
immunoreactive cells comprised 40% of the total pituitary cells in cultures. Somatotropes 
were approximately 10 jam in diameter (Fig. 1A). 
Functional identification of somatotropes in culture 
Changes in the intracellular calcium concentration (A[Ca2+];) mediate a variety of biological 
responses in both excitable and non excitable cells. GH cells were functionally identified by 
[Ca2+]j increase above the baseline following hGHRH application. Perfusion with hGHRH 
(10 |iM) for 2 min significantly increased [Ca2+]s by 53 + 1 nM (mean + SEM; n = 578; P < 
0.01; Fig. IB). Of the cells that responded to hGHRH, all (100%) also responded to L-585, 
that was applied 10 min after the application of hGHRH. Perfusion with 10 |xM L-585 for 2 
min produced a prompt transient increase in [Ca2+]j followed by the sustained decline to a 
plateau above the basal level. The initial increase in intracellular calcium reached a peak of 
68 + 2 nM (n = 578; P < 0.01) approximately 80 s after the onset of L-585 application (Fig. 
IB). Potassium at a concentration of 50 mM, a nonselective stimulus, elevated [Ca2+]j by 53 
±1 nM (P < 0.01) in all cells that responded to hGHRH and L-585 (Fig. IB). Some cells only 
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responded to the (nonspecific) stimulation with 50 mM K+ whereas others failed to respond 
to any stimuli (Fig. IB). 
L-585 induced release of GH in a dose dependent manner 
To demonstrate that calcium transient in cultured pituitary cells after application of L-585 
coincided with GH secretion, we performed experiments where reverse hemolytic plaque 
assay (RHPA) and [Ca2+]; measurements were done concurrently. Hemolytic plaques were 
formed only around cells that on calcium imaging responded to L-585, which identified them 
as GH-secreting somatotropes (Fig. IC). 
Before quantitatively studying the effects of L-585 on GH release, preliminary 
experiments were performed in which the maximum effective dose (EDmax) of L-585 for 
GH secretion was determined. When incubated with 10 nM, 100 nM, and 10 pM L-585, 
cultured pig somatotropes dose-dependently released GH with the EDmax of 100 nM. Using 
RHPA, the percentage of plaque forming cells (% PFC), and their mean plaque area (MPA) 
after 3 h incubation, were quantified. A total secretion index (TSI) was calculated by 
multiplying % PFC and MP A. Under basal conditions, GH plaques were formed in 24 
± 3 % of the pituitary cells in culture obtained from newborn pigs. The similar % PFC (about 
30%) under basal condition was observed in experiments with rats somatotropes (Niimi et al. 
1994; Mitani et al. 1996). The average size of the GH plaques in control cultures treated with 
vehicle was 1,892 ± 177 (am2. Incubation with 100 nM L-585 significantly increased the 
number and size of plaques. The fraction of somatotropes forming plaques was increased to 
40+6 % (P < 0.05; Fig. 2A) and the mean plaque area was 1.92 fold grater than controls 
(3,641 ±189 jam2; P < 0.01; Fig. 2B). L-585 also caused significant increase in TSI (x ÎO 2) 
(vehicle 5 + 1 vs 13 + 2; P < 0.01; Fig. 2C). 
Stimulatory effect of hGHRH and L-585 is receptor mediated 
To study the nature of GHS effect on somatotropes, ligands were applied in succession. The 
second application of 10 p,M hGHRH caused an increase [Ca2+]j in 63% of the cells (60 of 
96) that responded to the first application of hGHRH, and 59% of cells (57 of 96) that 
responded to the first application of 10 |iM L-585 responded to repeated application of L-
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585. A second application of 10 pM hGHRH and 10 pM L-585 did not have an additive 
effect on the increase in [Ca2+]; (32 ± 2 vs 20 +1 nM; 58 ± 4 vs 25 ±3 nM; Fig. 3B). 
Similarly, simultaneous application of hGHRH and L-585 in a concentration of 10 pM, also 
did not have an additive effect on the increase of [Ca2+]; (57 ± 4 nM; n = 77; Fig. 3C) but a 
sustained plateau phase of calcium increase was prolonged compared with either agonist 
alone. In parallely run controls average increase in [Ca24 ]; after application of 10 pM GHRH 
and 10 pM L-585 alone was 56 + 3 nM and 66 + 5 nM, respectively (n = 74; Fig 3A). 
To determine whether the effects of hGHRH and L-585 were receptor mediated we 
utilized a GHRH-receptor antagonist and a substance P analog with GHRH antagonistic 
properties. Application of 10 pM GHRH-receptor antagonist, (Phenylac-Tyr1, D-Arg2, p-
chloro-Phe6, Homoarg9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Homoarg29)-GRF (1-29) amide 
(human), for 10 min significantly decreased the rise in [Ca2+]f evoked by hGHRH compared 
to controls run in parallel (68 ± 8 nM, n = 27 vs 47 ± 3 nM, n = 68; P < 0.01; Fig. 4A,B). In 
contrast, application of GHRH-receptor antagonist did not influence the stimulatory effect of 
L-585 (80 ±11 nM, n = 27 vs 80 ± 8 nM, n = 70; Fig. 4B). Substance P analog, ([D-Arg1, D-
Phe5, D-Trp7,11]-SP), at a concentration of 10 pM, blocked the stimulatory effect of hGHRH 
(53 ± 2 nM, n = 48 vs 0 nM, n = 46) but it did not influence the stimulatory effect of L-585 
(75 + 4 nM, n = 48 vs 71 ± 4 nM, n = 44; Fig. 4C). These findings demonstrated that hGHRH 
and L-585 increase intracellular calcium concentration by acting through different receptors 
in cultured porcine somatotropes. 
Somatostatin (SS) dose-dependently decreased stimulatory effect of hGHRH and L-585 
Applications of S S at concentrations of 5 and 10 pM decreased intracellular calcium levels 
by 15 ±2 and 26 ± 3 nM, respectively (Fig. 4D). The blocking effect of SS on hGHRH and 
L-585 evoked increase in [Ca2+]; was dose dependent. Perfusion application of 10 pM SS for 
5 min before the application of 10 pM hGHRH and 10 pM L-585 abolished the stimulatory 
effect of both agonists (Fig. 4D). After pretreatment of the cultures with 5 pM SS for 5 min, 
59% of cells (26 of 44) responded to 10 pM hGHRH, and 57% of cells (25 of 44) responded 
to 10 pM L-585, while in parallel run controls 94% of cells (47 of 50) responded to 
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application of agonists. In the presence of 5 ^iM SS the increase in [Ca2+]j evoked by hGHRH 
was significantly smaller compared with controls (44 ± 3 vs 25 ± 4 nM; P < 0.01), while the 
peak increase of [Ca2+]; produced by L-585 was not significantly decreased (70 ±6 vs 59 
± 6 nM). 
Role of membrane depolarization and calcium channels in hGHRH and L-585 stimulatory 
To investigate the role of extracellular calcium in hGHRH and L-585 induced calcium 
transient in cultured somatotropes, cells were bathed in calcium depleted HEPES with the 
addition of 1 mM EGTA to yield an estimated free extracellular calcium level of 26 nM. We 
found that it was necessary to have some calcium in the bathing medium, otherwise cells 
detached from the culture substrate. Consistent with the ability of ligands to activate calcium 
channels, the stimulatory effect of hGHRH and L-585 was significantly decreased in calcium 
depleted saline (Fig. 5A,B). In parallely run control experiments in normal Ca2+HEPES, 88% 
of cells (70 of 80) responded to 10 |xM hGHRH and L-585. Only 11% (9 of 81) of cells 
responded to 10 ^M hGHRH in low Ca2+ HEPES. The average increase of [Ca2+]; was 22 + 7 
nM, which is significantly less (P < 0.05) than that evoked with hGHRH in normal Ca2+ 
HEPES (52 ± 4 nM). In contrast, 52% (42 from 81) of the cells responded to 10 (J.M L-585 in 
low Ca2+ HEPES (Fig. 5B). The amplitude of L-585 evoked transient increase in [Ca2+]; in 
low calcium HEPES was significantly smaller than in normal Ca2+ HEPES (67 ± 5 vs 34 ± 2 
nM; P < 0.01), and the second, sustained phase of calcium increase was almost abolished 
(Fig. 5B). These results suggest that extracellular calcium has an important role in the effect 
of hGHRH and L-585 on GH secretory cells. 
It has been demonstrated that GHRP-induced depolarization of somatotropes can 
activate voltage dependent calcium channels and result in an increase of [Ca2+]; (Herrington & 
Hille 1994). To investigate the contribution of voltage dependent Ca2+ channels in calcium 
influx evoked by hGHRH and L-585, experiments were performed in the presence of 
nifedipine, an antagonist of the L-type calcium channel. In control cultures 10 jxM hGHRH 
and 10 |xM L-585 evoked a response in 94% of the cells (136 of 144). Application of 10 |_iM 
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hGHRH, in the presence of nifedipine, evoked a response in 88% of the cells (134 of 152) 
and Ca2+transient in those cells was significantly decreased (55 ± 2 vs 25 ± 1 nM; P < 0.01; 
Fig. 5C). In the presence of 10 |_iM nifedipine, 91% of the cells (139 of 152) responded to 10 
joM L-585. The average increase in [Ca2+]; was significantly smaller (70 ± 3 vs 47 ± 2 nM; P 
< 0.01; Fig. 5C), and the duration of the sustained phase of calcium increase was brief. 
To determine the role of Na+ in hGHRH and L-585 induced calcium transients 
cultures were bathed in zero Na+ solution (sodium was replaced with choline). Application of 
10 joM hGHRH in normal HEPES solution in parallel run control experiments evoked an 
increase in [Ca2+]j in 92% of the cells (126 of 137). In zero Na+HEPES, 71% of the cells (112 
of 157) responded to 10 pM hGHRH, and the average amplitude of calcium increase was 19 
± 1 nM, a significantly smaller response compared to parallel run controls of 58 ± 2 nM (P < 
0.01; Fig. 5D). Similarly, 84% of the cells (132 of 157) responded to 10 pM L-585 in zero 
Na+ HEPES with 49 + 3 nM increase in [Ca2+](; the effect was significantly smaller compared 
with parallel run controls (61 ± 3 nM; P < 0.01; Fig. 5D). In zero Na+ HEPES the effect of 
50 mM K+ on calcium transient was 40% of that recorded in normal HEPES (51± 2 vs 21 ± 1 
nM; P < 0.01; Fig. 5D). These results further suggest an involvement of Na+ dependent 
depolarization in calcium transients induced by both hGHRH and L-585. 
Signal transduction pathways, phospholipase C (PLC), and adenylyl cyclase - cyclic 
adenosine 3,5-monophosphate (AC-cAMP), are activated by GH secretagogues 
Results with the application of L-585 in low Ca2+ solution suggest that in L-585 induced GH 
secretion, extracellular Ca2+ has an important role but that intracellular Ca2+ has some role, 
too. The involvement of intracellular Ca2+ stores in hGHRH and L-585 action was further 
investigated in experiments with U73122, a selective inhibitor of phospholipase C (PLC) 
(Smith et al. 1990). Application of 10 pM U73122 for 10 min significantly decreased the 
effect of hGHRH on calcium transient (53 ± 3 nM, n = 75 vs 14 ± 1 nM, n = 62; P < 0.01). 
Inhibition of PLC by 10 pM U73122, also significantly reduced the effect of L-585 (77 ± 5 
nM, re = 75 vs 12 + 1 nM, n = 110; P < 0.01), implying an involvement of the PLC-IP3 
pathway (Fig. 6). 
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It has been shown that GHRH activates the cyclic adenosine 3,5-monophosphate 
pathway (Cheng et al. 1989). To determine whether L-585 activates this pathway, cell 
cultures were pretreated with SQ-22536, an adenylyl cyclase inhibitor (Tamaoki et al. 1993). 
SQ-22536 blocked the stimulatory effect of hGHRH and L-585 in a dose dependent manner. 
After 10 min application of SQ-22536 in concentrations of 50, 100, and 200 pM, the 
amplitude of [Ca2+]; increase evoked by 10 |iM hGHRH was decreased 51% (P < 0.01), 68% 
(P < 0.01), and 72% (P < 0.01), respectively (Fig. 7A). Pretreatment with SQ-22536 at a 
concentration of 50 |^M decreased the stimulatory effect of L-585 to 41% (P < 0.01), while 
SQ-22536 in concentrations of 100 and 200 (J.M had more prominent effect and decreased 
stimulatory effect of L-585 to 55% (P < 0.01) (Fig. 7B). 
Discussion 
Porcine pituitary cells have a regulated secretory pathway utilized by secretory 
vesicles that fuse with the plasma membrane in response to a physiological stimulus such as 
GHRH or L-585 (Cho et al. 2002). Results from our experiments with simultaneous 
measurements of RHPA and calcium transients have shown that L-585 evoked an increase in 
[Ca2+]; that coincided with GH release. The amplitude of [Ca2+]; increase was greater after 
exposure to L-585 compared with hGHRH at the same micromolar concentration. GH 
secretion appears to be directly related to intracellular free calcium concentration (Lussier et 
al. 1991a) and our calcium imaging experiments indicate that L-585 was more potent than 
hGHRH in the rapid release of GH. Our earlier in vivo experiments in the pig have shown 
that L-585 was more efficacious than GHRH in releasing significantly greater amounts of 
circulating GH (Hickey et al. 1996). These in vivo experiments also showed that GHRH and 
L-585 have a synergistic effect on GH secretion (Hickey et al. 1996). Simultaneous 
application of hGHRH and L-585 in the present study, however, did not have an additive 
effect on intracellular calcium concentration in cultured porcine somatotropes. 
Somatostatin abolished the effect of hGHRH and L-585, but at a lower concentration, 
it was more effective in suppressing the stimulatory effect of hGHRH compared with L-585. 
The effect of S S can be mediated by an inhibition of cAMP formation (Chen et al. 1996) or 
via decreased Ca2+ influx as a result of an increase in K+ conductance and hyperpolarization 
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of somatotropes (Lussier et al. 1991 b). GHS depolarize the plasma membrane of 
somatotropes by inhibiting K+ channels, and have been suggested to behave as a functional 
antagonist of somatostatin (Smith et al. 1997). 
GHRH receptor antagonist and a substance-P-analog with GHRH receptor antagonist 
properties did not influence the stimulatory effect of L-585, while they decreased and 
abolished the stimulatory effect of hGHRH on calcium transient, suggesting that L-585 and 
hGHRH act via different receptors on porcine somatotropes. Similarly, Smith et al. (1993) 
have shown that activity of L-692,429 can be blocked by both peptide and nonpeptidyl 
antagonists of GHRP-6, but not by an antagonist of GHRH. Contrary to our results on 
cultured porcine somatotropes, the SP analog in rats significantly reduced both GHRP-6- and 
L-692,429-stimulated GH response but had no effect in inhibiting GHRH-stimulated GH 
response (Cheng et al. 1994). 
The depletion of extracellular calcium greatly diminished but did not abolish the 
stimulatory effect of hGHRH and L-585 on porcine somatotropes. This suggests that both 
GHRH and L-585 mobilize Ca2+ from intracellular stores, but Ca2+ influx has a major 
contribution to calcium transient. In somatotropes the major Ca2+ channels are the voltage-
gated T- and L-types (Chen et al. 1990). Perfusion of porcine cells with nifedipine 
significantly decreased the effect of hGHRH and L-585. This indicates an involvement of L-
type Ca2+ channels in calcium influx induced by hGHRH and L-585, and that influx of 
calcium is a crucial step in the action of GHS. 
The stimulatory effect of hGHRH and L-585 was greatly attenuated in a zero Na+ 
environment, suggesting that both ligands can depolarize somatotropes at least, in part, 
through sodium channels. GHRH transiently increases Na+ and Ca2+ current while it 
decreases membrane K+ conductance, which leads to depolarization and an influx of 
extracellular Ca2+ (Chen et al. 1994). Potassium channels may also be involved in the action 
of L-585, because electrophysiology studies showed that peptidomimetics blocked K+ 
currents in somatotropes, resulting in a depolarization and electrical spiking to enhance Ca2+ 
entry through voltage gated channels (Smith et al. 1997). In our experiments the increase in 
[Ca2+]; after applying K+ was significantly decreased by nifedipine and in sodium free 
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solution, indicating that calcium and sodium channels were involved in depolarization of 
porcine somatotropes. 
In this study, the few cells that responded to hGHRH in low calcium HEPES likely 
were low density (LD) cells. The first phase of L-585-evoked calcium increase resulted from 
intracellular Ca2+ mobilization, whereas the second phase represents calcium influx, because 
in low calcium HEPES, in nifedipine and in zero sodium HEPES, this second, sustained 
phase was almost abolished. In rats and pigs, it has been demonstrated that two 
morphologically and functionally distinct somatotrope subpopulations exist with LD and 
high density (HD) cells (Lindstrom & Savendahl 1996; Ramirez et al. 1999). In pigs 
blockade of Ca2+ influx with CoCl2 reduced the GHRH-stimulated GH secretion in both LD 
and HD somatotropes, while depletion of thapsigargin-sensitive intracellular calcium stores 
only decreased the secretory response to GHRH in LD cells (Ramirez et al. 1999). 
Pretreatment of porcine somatotropes with SQ-22536, an adenylyl cyclase inhibitor, 
decreased the stimulatory effect of hGHRH and L-585 on calcium transient in a dose-
dependent manner, implying that the binding of hGHRH and L-585 to their receptors 
activates adenylyl cyclase. GHRP-2 applied to ovine somatotropes dose-dependently 
increased intracellular cAMP levels, whereas the GHRP-2-stimulated GH secretion was 
blocked by the inhibitor of adenylyl cyclase (MDL 12 330A) and by a cAMP binding 
antagonist (Rp-cAMP). GHRP-2 did not increase cAMP levels in rat somatotropes, 
suggesting the existence of several subtypes of GHS-R that are variably expressed in 
different species (Wu et al. 1996). 
In our experiments U73122, a PLC inhibitor, decreased the effect of hGHRH on 
calcium transient, indicating the involvement of PLC/IP3 pathway in hGHRH action on 
porcine somatotropes. Ramirez et al. (1999) demonstrated that the adenylyl cyclase inhibitior 
(MDL-12,3 3 OA) abolished GHRH-stimulated GH release in both LD and HD subpopulations 
of porcine somatotropes, whereas U73122 only partially reduced this effect in LD cells. In 
the present investigation, U73122 decreased the transient increase in [Ca2+]j evoked by L-
585. Consistent with activation of this pathway were the observations that GHRP-6 and non-
peptidergic GHSs increased PI turnover, and caused translocation of protein kinase C (PKC) 
(Adams et al. 1995, Mau et al. 1995). The activation and interplay of several pathways of 
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signal transduction mediate the effect of GHS in mobilazing Ca2+, cAMP, protein kinase A 
and C, and phospholipase C (Smith et al. 1997, Muller et al. 1999). 
In summary, L-585 in porcine somatotropes activates AC and PLC pathways, 
suggesting that it may act through different receptors that are coupled to Gs and Gq. 
Activation of these different signal transduction pathways mobilize calcium from internal 
stores during the first phase of the L-585-induced increase in [Ca2+]j. A second prolonged 
phase due to calcium influx results from somatotrope depolarization by L-585 acting on Na+ 
and K+ channels, and the activation of calcium channels through different second messengers. 
RHP A of cultured porcine somatotropes confirmed a connection between the L-585-evoked 
mobilization of calcium and GH release. 
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Figure 1 Morphological and functional identification of cultured porcine somatotropes: 
A) Cells stained with anti-GH antibody in cultured porcine pituitary cells. Magnification 
40 x. 
B) The sequence of color images and kinetics of the [Ca2+]j changes illustrate response 
of isolated pituitary cells to application of 10 p,M hGHRH, 10 p,M L-585 and 50 mM K+. 
The GH secretory cells (red x and red line in time-course histogram) responded to 
application of hGHRH, L-585 and 50 mM K+. The non GH-secretory cells responded to 
nonspecific stimulation of the 50 mM K+ (green x and green line in time-course 
histogram) and nonexcitable cells (possible stellate cells) failed to respond to any of 
stimuli (blue x and blue line in time-course histogram). 
C) Calcium transient induced by L-585 coincides with release of GH. Bath application of 
L-585 induced calcium transient in one of two cells illustrated in a and b images and in 
time course histogram in d. Phase contrast images in c illustrate formation of plaque only 
around the cell that responded with calcium transient to L-585 application in b. 
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Figure 2 Treatment with L-585 increases GH secretion from isolated porcine 
somatotropes determined by reverse hemolytic plaque assay (RHPA): 
A) Percentages of GH-plaque forming cells (% PFC) in dispersed anterior pituitary cells 
when exposed for 3 h to vehicle (control) or 100 nM L-585. The results are expressed as 
the mean ± SEM for three separate plaque assays. Two hundred pituitary cells were 
counted per assay (*, P < 0.05 vs vehicle). 
B) The mean plaque areas (MP A) of somatotropes in RHP A described in A are shown on 
phase contrast images (a) and on histograms (b). 
a) Monolayers prepared from the same protein-A labeled ovine erythrocytes (small cells) 
and somatotropes (large cells) derived from 2-day old pigs. The cultures were treated 
with control medium and L-585 100 nM. The cultures were incubated with GH-antibody 
(1:60) for 3 h, exposed to complement (1:40) for 50 min, then fixed in 1% glutaraldehyde 
for 50 min. Phase contrast images show the increase in size of plaques (pale areas in the 
monolayer of red blood cells) formed by somatotropes (oval cells in the center of each 
plaque) treated with L-585. 
b) The MP A of somatotropes are expressed as the mean ± SEM of the mean plaque areas 
of 100 plaque forming cells from 3 separate plaque assays (**, P < 0.01 vs vehicle). 
C) The total secretion index (TSI) of somatotropes in RHP A described in A, is calculated 
by multiplying PFC and MP A (**, P < 0.01 vs vehicle). 
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Figure 3 hGHRH and L-585 induce calcium transient in isolated porcine somatotropes: 
A) Increase in [Ca2+]; after application of 10 (J.M hGHRH, 10 (J.M L-585, and 50 mM K+ 
(n = 51). 
B) The second application of 10 p,M hGHRH and 10 p,M L-585 did not have an additive 
effect on the [Ca2+]; increase (n = 57). 
C) Simultaneous application of 10 |iM hGHRH and 10 |j,M L-585, did not cause an additive 
effect on the increase in [Ca2+]; (n = 58 ). 
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Figure 4 hGHRH and L-585 increased [Ca2+]; in isolated porcine somatotropes acting 
through different receptors: 
A) Control effect of 10 |_iM hGHRH, 10 jo-M L-585, and 50 mM K+ on calcium transient in 
isolated porcine somatotropes (n = 21). 
B) Application of GHRH receptor-antagonist, Phenylac-Tyr1, D-Arg2, p-chloro-Phe6, 
Homoarg9, Tyr (Me)10, Abu15, Nle27, D-Arg28, Homoarg29)-GRF (1-29) amide (human), 
decreased stimulatory effect of 10 joM hGHRH, while it had no influence on L-585 effect (n 
= 30). 
C) Substance P analog abolished only the effect of hGHRH, but not that of L-585 (n = 44). 
D) Application of 10 (iM SS decreased [Ca2+]; and blocked the stimulatory effect of hGHRH 
and L-585 (n - 10). 
Figure 5 Influx of calcium is involved in hGHRH and L-585 induced calcium transient in 
isolated porcine somatotropes: 
A) Control effect of 10 jxM hGHRH, 10 |o,M L-585, and 50 mM K+ on calcium transient 
in isolated porcine somatotropes (n = 40). 
B) Depletion of Ca2+ from bathing solution dramatically decreased the stimulatory effect 
of hGHRH and L-585 on isolated somatotropes (n = 5). 
C) Perfusion of culture with 10 (iM nifedipine, a blocker of L-type Ca channels, 
significantly decreased stimulatory effect of hGHRH, L-585, and 50 mM K+ on isolated 
somatotropes (n - 70). 
D) Removal of Na+ ions from the bathing solution significantly decreased the effect of 10 
|iM hGHRH, 10 jj,M L-585, and 50 mM K+ on calcium transient (n = 37). 
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Figure 6 PLC-IP3 pathway is involved in stimulatory effect of hGHRH and L-585 on 
cultured porcine somatotropes: 
A) Control effect of 10 j^M hGHRH, 10 p,M L-585, and 50 mM K+ on calcium transient in 
isolated porcine somatotropes (n = 36). 
B) Pretreatment of the cultured porcine pitutary cells with 10 (a,M U73122 significantly 
decreased the stimulatory effect of hGHRH and L-585 (P < 0.01; n = 18). 
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Figure 7 Application of SQ-22536 (SQ), an adenylyl cyclase inhibitor, dose dependently 
blocked the stimulatory effect of hGHRH and L-585: 
A) Dose dependent effect of SQ on hGHRH induced calcium transient in isolated porcine 
somatotropes [*, P < 0.01 control (hGHRH) vs hGHRH+SQ]. 
B) Dose dependent effect of SQ on L-585 induced calcium transient in isolated porcine 
somatotropes [*, P < 0.01 control (L-585) vs L-585+SQ], 
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CHAPTER 3. STRUCTURE AND DYNAMICS OF THE FUSION PORES 
IN LIVE GH-SECRETING CELLS REVEALED USING ATOMIC 
FORCE MICROSCOPY 
A paper published in Endocrinology (2002) 
Sang-Joon Cho, Ksenija Jeftinija, Aleksandra Glavaski, Srdija Jeftinija, Bhanu P. Jena and 
Lloyd L. Anderson 
Abstract 
Earlier studies in live pancreatic acinar cells identified new cellular structures at the cell 
plasma membrane called 'pits' and 'depressions', where membrane-bound secretory vesicles 
dock and fuse to release vesicular contents. In the current study, using atomic force 
microscopy we identify similar structures at the plasma membrane of GH-secreting cells of 
the pituitary and implicate their involvement in hormone release. Pits containing 100-200 nm 
in diameter depressions or fusion pores were identified in resting GH-secreting cells. 
Following stimulation of secretion the size of depression enlarged and gold-tagged GH 
antibody were found to bind to the pit structures in the stimulated GH cells. This study 
documents for the first time the presence of these structures and their involvement in 
secretions in a neuroendocrine cell. 
Introduction 
Until recently (1 and unpublished data), our understanding of secretory vesicle fusion 
at the cell plasma membrane was obtained from morphological (2-5), electrophysiological 
(6-11), and biochemical studies (2, 12-15) all suggesting the presence of 'fusion pores' at the 
cell plasma membrane. Using atomic force microscopy (AFM), the structure and dynamics of 
the 'fusion pore' were first revealed and examined in live pancreatic acinar cells (1 and 
unpublished data). In live resting pancreatic acinar cells, 'pits' measuring 0.5-2 |im and 
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containing 3-20 'depressions' of 100-180 nm diameter were identified only at the apical 
region of these cells where membrane-bound secretory vesicles are known to dock and fuse. 
Following stimulation of secretion, only 'depression' enlarged and returned to resting size 
following completion of secretion. Exposure of acinar cells to cytochalasin B, a fungal toxin 
that inhibits actin polymerization, resulted in a 50-60% loss of stimulable amylase secretion. 
A significant decrease in depression diameter was also observed in acinar cells exposed to the 
fungal toxin. To determine if similar structures are present in neuroendocrine cells, the GH-
secreting cell of the pig pituitary was studied using AFM. Results from this study 
demonstrate the presence of pits and depressions in GH-secreting cells of the pituitary and 
their involvement in hormone release. 
Material and Methods 
Experimental animals 
Yorkshire pigs, raised at the Iowa State University Animal Nutrition Farm, were used for 
these experiments. Newborn pigs, 1-8 days of age, were killed with electricity and 
decapitated. Pituitary glands were immediately removed and collected in cold sterile BBSS 
solution (4 °C). Posterior lobes were discarded and anterior lobes were transferred to a sterile 
cold (4 °C) MEM-0.1% BSA medium. Animal care and experimental protocols were in 
accordance with the guidelines and approval of the Iowa State University Committee on 
Animal Care. 
Isolation and stimulation of GH-secreting cells 
The protocol used for establishing primary cell cultures from pig anterior pituitary gland is a 
modification of procedure used for establishing neuronal cultures (16). In brief, tissue was 
incubated with 2.5% papain solution for 40min at 37 °C. After the incubation, tissue was 
mechanically dispersed in a presence of 1 ml of culture medium by triturating through a 1-ml 
fire-polished glass pipette 8-10 times and plated on the poly-L-lysine (1 mg/ml, MW 
100,000; Sigma) coated dishes. Cells were incubated overnight at 37 °C in a humidified 5% 
C02/95% air atmosphere to allow them to adhere. Culture medium consisted of Eagle's MEM 
supplemented with 10% FBS and 40 mM glucose, 2 mM L-glutamine, 1 mM pyruvate, 14 
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mM sodium bicarbonate and penicillin/streptomycin. Cells in PBS, were stimulated with 20 
|o,M of the GH secretagogue L-692,585. 
Assay of GH-secretion using Reverse Hemolytic Plaque Assay 
Reverse Hemolytic Plaque Assays (RHPA) were performed using a minor modification of 
the method of (17). Staphylococcus protein A was coupled to ovine red blood cells using 
0.1% CrCl3. Isolated pituitary cell were incubated for 48 h to allow cells to acclimate. Cells 
were then treated with trypsin (2.5 mg trypsin in 10 ml MEM-0.1% BSA) to detach the cells 
from the culture dish. After gentle trituration using a fire-polished glass pipette, cells were 
separated by centrifugation (1500 x g for 10 min), washed twice in MEM-0.1% BSA. A cell 
concentration of 2.5 x 105 cells/ml was used in RHP A experiments. A 1:1 pituitary cell to 
50% protein A-labeled erythrocyte solution were mixed, and infused into Cunningham slide 
chambers. The chambers with the cell infusion were preincubated for 50 min at 37 °C in 5% 
C02-95% air. Slides were pretreated with poly-L-lysine (0.1 mg/ml; MW 100,000), to ensure 
cell adhesion. After incubation, the chambers were rinsed with DMEM-0.1% BSA, followed 
by addition of anti porcine GH raised in monkey (1:60 dilution in DMEM-0.1% BSA), in the 
presence and absence of 100 nM L692,585. After 3 h incubation, plaque formation was 
initiated by infusing, guinea pig complement (1:40 in DMEM-0.1% BSA). The reaction was 
terminated after 50 min by infusion of 1% glutaraldehyde. The secretion index is represented 
by the size of the plaque. These isolated cells were used in our AFM studies. 
Atomic Force Microscopy 
'Pits' and 'depressions' at the plasma membrane in live and fixed GH secreting, cells (n = 
24) in PBS pH 7.5 were imaged by the AFM (Bioscope III, Digital Instruments) using- both 
contact and tapping mode. All images presented in this manuscript were obtained in the 
"tapping" mode in fluid, using silicon nitride tips with a spring constant of 0.06 Nm and 
an imaging force of <400 nN. Images were obtained at line frequencies of 1 Hz, with 512 
lines per image, and constant image gains. Topographical dimensions of 'pits' and 
'depressions' at the cell plasma membrane were analyzed using the software 
nanoscopeIIIa4.43r8 supplied by Digital Instruments. 
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Immunogold AFM 
Following stimulation of secretion using 20 pM L-092,585, live GH secreting cells of the 
pituitary were exposed to 1:200 dilution of Growth Hormone-specific antibody, and 30 nm 
gold conjugated secondary antibody, washed in PBS, prior to AFM imaging in PBS at room 
temperature. 
Cell Fixation and immunogold localization 
Following stimulation of secretion using 20 jj,M L-692,585, live GH secreting cells were 
fixed for 30 min using ice-cold 2.5% paraformaldehyde in PBS. Cells were then washed in 
PBS, followed by labeling with 1:200 dilution of Growth Hormone-specific antibody, Lind 
30 nm gold conjugated secondary antibody, washed in PBS, prior to AFM imaging in PBS at 
room temperature. 
Results and Discussion 
Reverse hemolytic plaque assay on isolated GH secreting cells of the pig pituitary 
demonstrated GH release following exposure to L-692,585 (Fig. 1). Examination of resting 
and stimulated GH cells demonstrates no detectable changes following fixation (Fig. 2). 
Examination of resting GH cells revealed the presence of 'pits' and 'depressions' at the 
plasma membrane. Depressions in resting cells measure 154 ± 4.5 nm (mean ± SE). 
However, following exposure of GH cells to the secretagogue L-692,585, a 40% increase in 
the size (215 ± 4.6 nm; P < 0.01) of 'depressions' is demonstrated (Fig. 3, 4). When 
stimulated live cells were exposed to 30 nm-gold-tagged GH-antibody, gold particles were 
found to decorate 'pit' and 'depression' structures (Fig. 3). Aldehydes fixation of biological 
samples is known to result in decreased elasticity and increased hardness (18, 19 and 
personal observation). Since force spectroscopy is used to image objects using the AFM, less 
elastic samples are better resolved. From studies using that pancreatic acinar cells 
(unpublished), it was determined 1-h treatment of ice-cold 2.5% paraformaldehyde in 
phosphate buffered saline, pH 7.5, was ideal in retaining the structural integrity of 'pits' and 
'depressions'. No detectable changes were identified in live cells following fixation. To 
obtain high resolution images of the cells, and the 'pits' and 'depressions' and to determine 
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the distribution of 30 nm GH-immunogold labeling, stimulated GH cells were fixed 
following immunogold labeling. In conformation with our observation in live GH cells, AFM 
images of the immunolabeled fixed cells, demonstrate specific localization of immunogold at 
'depressions' (Fig. 4), implicating them to be secretory sites at the cell plasma membrane. In 
agreement with earlier studies in pancreatic acinar cells, the GH-secreting neuroendocrine 
cells of the pituitary demonstrate the presence of 'pits' and 'depressions' at the plasma 
membrane, where secretory vesicles dock and fuse to release vesicular contents. The presence 
of 'pits' and 'depressions' in both exocrine and neuroendocrine cells suggests that these 
structures may be universal to secretory cells, where exocytosis occurs (Fig. 5). 
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Fig. 1. Light microscopy revealing the extent of growth hormone release from isolated GH 
cells of the pituitary gland, in a typical Reverse Hemolytic Plaque Assay. Larger the plaque 
(clear area), more the release. Note the presence of a small plaque in a resting GH cell (A), 
compared to a L-692,585 stimulated cell (B). 
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Fig. 2. Atomic Force Microscopy (AFM) performed on whole GH cells. AFM. micrograph 
of a live (A) and fixed (B) GH secreting cells, imaged in fluid (PBS). 
Fig. 3. High resolution Atomic Force Microscopy (AFM) performed on live GH secreting 
cells, showing a single 'pit' with 3-4 'depressions' (top panel). The scan line in the middle 
panel depicts the relative height and depth between arrows, and the bottom panel is section 
analysis of two 'depressions' showing their relative depth and diameter. (A) in the resting 
cell and (B) when the same cell is GH-secretagogue stimulated, and (C) following exposure 
to 30 nm-gold-tagged GH-antibody following the stimulation. Note the enlargement of the 
'depressions', following stimulation of secretion [(A) compared with (B)] and decoration of 
the 30 nm-gold-tagged GH-antibody (C) at the edges and one within a 'depressions'. 
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Control 
Control 
GH Ab + Gold 
Fig. 4. High resolution Atomic Force Microscopy (AFM) performed on resting and 
stimulated GH secreting cells, after fixation. Note a large area of a cell surface in resting (A) 
and in a stimulated (B) cell. AFM micrographs of a 'pit' with 'depressions' in resting cell 
(C), again clearly demonstrating the enlargement of 'depressions' or fusion pores following 
stimulation of secretion (D). Exposure of 'pits' in a stimulated cell (E) to 30 nm gold-tagged 
GH-antibody, results in binding of released growth hormone at the site to 30 nm gold-tagged 
GH-antibody (F). Note the loss of fusion pores due to large amounts of gold-tagged antibody 
binding at these sites. 
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Actin 
Fig. 5. Schematic diagrams depict cross sectional views at cell plasma lipid membrane of a 
'pit' (green arrowhead) and 'depressions' (red arrow head) as well as a vesicle which 
contains hormone (GH), within the cell cytoplasm. Immediately following GH-secretagogue 
stimulation, the secretory vesicle containing hormone docks and fuses with the 'depression' 
(A) and then releases hormone (B) through the fusion pores of the depression' (yellow 
arrow). After hormone release from the vesicle (C), the 'depression' becomes smaller and the 
vesicle returns to the cellular cytoplasm. 
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CHAPTER 4. STIMULATORY EFFECT OF GHRELIN ON ISOLATED 
PORCINE SOMATOTROPES 
Paper submitted to Neuroendocrinology 
Aleksandra Glavaski-Joksimovic, Ksenija Jeftinija, Colin G. Scanes, Lloyd L. Anderson, and 
Srdija Jeftinija 
Absrtact 
Research on the mechanism for growth hormone secretagogue (GHS) induction of 
growth hormone (GH) secretion led to the discovery of GH secretagogue receptor (GHS-R) 
and later to ghrelin, an endogenous ligand for GHS-R. The ability of ghrelin to induce an 
increase in intracellular Ca2+ concentration ([Ca2+];) in somatotropes was examined in 
dispersed porcine pituitary cells using a calcium imaging system. Somatotropes were 
functionally identified by application of human growth hormone releasing hormone 
(hGHRH). Ghrelin increased [Ca2+]; in a dose dependent manner in 98 % of the cells that 
responded to hGHRH. In the presence of (D-Lys3)-GHRP-6, a specific receptor antagonist of 
GHS-R, the increase in [Ca2+]; evoked by ghrelin was decreased. Pretreatment of cultures 
with somatostatin, or neuropeptide Y, reduced the ghrelin-induced increase of [Ca2+]j. The 
stimulatory effect of ghrelin on somatotropes was greatly attenuated in low calcium saline 
and blocked by nifedipine, a L-calcium channel blocker, suggesting involvement of calcium 
channels. In a zero Na+ solution* the stimulatory effect of ghrelin on somatotropes was 
decreased, suggesting that beside calcium channels, sodium channels are also involved in 
ghrelin-induced calcium transients. Either SQ-22536, an adenylyl cyclase (AC) inhibitor, or 
U73122, a phospholipase C (PLC) inhibitor, decreased the stimulatory effects of ghrelin on 
[Ca2+]; transient indicating the involvement of AC-cyclic adenosine monophosphate (cAMP) 
and PLC- inositol 1,4,5-trisphosphate IP3 pathways. 
The nonpeptidyl GHS, L-692,585 (L-585), induced changes in [Ca2+]; similar to those 
observed with ghrelin. Application of L-585 after ghrelin, did not have additive effect on 
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[Ca2+]j. Pre-application of L-585 blocked the stimulatory effect of ghrelin on somatotropes. 
Simultaneous application of ghrelin and L-585 did not cause an additive increase in [Ca2+]j. 
Our results suggest that the action of ghrelin and synthetic GHS closely parallel each other, in 
a manner that is consistent with an increase of hormone secretion. 
Introduction 
GROWTH HORMONE (GH) secretion from the pituitary gland is controlled by two 
hypothalamic peptides - stimulatory - GH releasing hormone (GHRH) and inhibitory -
somatostatin (SRIH). GH participates in its own rhythmic secretion through feedback action 
on GHRH and SRIH neurons [1]. Peptidyl and nonpeptidyl compounds, known as growth 
hormone secretagogues (GHS), can also stimulate GH secretion both in vivo and in vitro [2]. 
GH releasing peptides (GHRP) were the first generation of GHS [3, 4]. Later nonpeptidyl 
classes of benzolactam and spiroindolamine GHS with better oral bioavailability and 
pharmacokinetics properties were developed [5], The mechanism of action of GHS is not 
fully established. There is both a direct effect on the anterior pituitary gland and an indirect 
effect on the hypothalamus. The latter suggests that exogenous GHS may induce the release 
of another hypothalamic factor with GH-releasing capabilities (U-factor) [2, 3]. The direct 
effect of GHS on GH secretion is_through an interaction with a specific receptor named GHS-
R. These are distinct from the GHRH receptor [6], The GHS-R, a typical G-protein-coupled 
seven-transmembrane receptor, has been cloned in pigs, humans, and rats [7, 8], 
Ghrelin, an endogenous ligand for GHS-R, is a 28-amino acid peptide with an n-
octanoyl modification at Ser3 residue that is essential for its biological activity [9, 10]. 
Ghrelin is predominantly produced by the stomach, whereas lower amounts are derived from 
hypothalamus and various peripheral tissues [9, 11]. Ghrelin receptors (GHS-R) are widely 
distributed e.g. in the pituitary, hypothalamus, stomach, heart, blood vessels, lung, pancreas, 
intestine, kidney, adipose tissue and immune system [11, 12]. This suggests that ghrelin can 
have peripheral and central effects in addition to having a powerful effect on the secretion of 
GH. Moreover, ghrelin signals directly to the hypothalamic regulatory nuclei those control 
energy homeostasis, and, therefore, might regulate growth process in an integrated manner 
[13]. 
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Ghrelin has been demonstrated to induce GH secretion from the pituitary in vivo and 
in vitro [9, 14]. Recently ghrelin, has been shown to stimulate GH release in humans in a 
dose dependent manner [15, 16, 17]. The effects of ghrelin exhibit a similar time course for 
GH release to that with other GHS [15]. Several studies confirm that the actions of ghrelin 
and peptidyl GHS closely parallel each other [16,18]. 
The present study examined the signal transduction pathways of ghrelin in isolated 
porcine somatotropes and the interaction between ghrelin and nonpeptidyl GHS, L-692,585 
(L-585). An understanding of the molecular mechanisms by which ghrelin and GHS 
modulate GH secretion is of particular interest in the regulation of GH for muscle accretion 
and somatic growth. 
Materials and Methods 
Chemicals 
Fetal bovine serum (FBS), horse serum (HS), minimum essential medium (MEM), 
Dulbecco's modified Eagle's medium (DMEM) and Earle's balanced salt solutions (BBSS) 
were purchased from Gibco-Invitrogen Co. (Carlsbad, CA, USA). HEPES, ethyleneglycol-
bis-(P-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA), papain solution, trypsin-
inhibitor, penicillin-streptomycin solution, poly-L-lysine, L-cysteine, L-glutamine, sodium 
pyruvate, bovine serum albumin (BSA) and nifedipine were obtained from Sigma-Aldrich 
Co. (St. Louis, MO, USA). Paraformaldehyde was obtained from Fisher Chemical (Fair 
Lawn, NJ, USA). Fura 2/AM and Pluronic F-127 were purchased from Molecular Probes 
(Eugene, OR, USA). ABC kit was obtained from Vector Laboratories (Burlingame, CA, 
USA). Somatostatin-14 (SRIH), Porcine Neuropeptide Y (NPY) and (D-Lys3)-GHRP-6 were 
obtained from Bachem California, Inc. (Torrance, CA, USA). U73122 and SQ-22536 were 
purchased from Biomol Research Laboratories (Plymouth Meeting, PA, USA). Ghrelin 
(human) was purchased from American Peptide Company, Inc. (Sunnyvale, CA, USA). 
Human GHRH and anti-porcine GH antibody were gifts from Dr A F Parlow, NIDDK 
National Hormone and Pituitary Program (Torrance, CA, USA). L-692,585 (L-585) was a 
gift from Dr G J Hickey, Merck Research Laboratories, Rahway, NJ, USA. 
75 
Experimental animals 
Yorkshire pigs, raised at the Iowa State University Animal Nutrition Farm, were used for 
these experiments. Animal care and experimental protocols were in accordance with the 
guidelines and approval of the Iowa State University Committee on Animal Care. 
Preparation of cell cultures 
Newborn pigs, 1-8 days of age (n = 26), were killed with electric shock and decapitated. 
Pituitary glands were immediately removed. The pituitary glands were collected in cold 
sterile BBSS solution (4°C). Anterior lobes were transferred to a sterile cold (4 °C) MEM-0.1 
% BSA medium. Primary cell cultures from neonatal anterior pituitary gland were 
established using a modified method of Huettner & Baughman [19]. Tissues from two 
animals were incubated 50 min at 37 °C in 2 ml of EBSS-papain solution (1.54 mg/ml). 
After incubation, the tissue was rinsed with BBSS solution and incubated for 5 min in 
trypsin-inhibitor solution (1 mg/ml). After being rinsed, once with BBSS solution and once 
with DMEM-0.1 % BSA medium, the tissue was mechanically dispersed in DMEM-0.1 % 
BSA medium by triturating through a firepolished glass pipette. The undigested tissue was 
allowed to sediment. The supernatant containing cells was removed and filtered through 
sterile filter. Cells were plated onto poly-L-lysine (0.1 mg/ml; 100,000 KD) coated glass 
coverslips (at a density of 2 x 105 cells). Cells were allowed to attach, and then after 3-4 h 
DMEM-0.1 % BSA medium was exchanged with DMEM medium supplemented with 10 % 
horse serum and 1 ml penicillin-streptomycin solution per 100 ml medium. Cultures were 
maintained at 37 °C in a humidified 5 % C02/95 % air atmosphere. Studies examining effects 
of ghrelin on changes in intracellular calcium concentrations [Ca2+]j in somatotropes were 
carried out after 2 days in culture. The presence of somatotropes was confirmed by 
immunocytochemical methods. 
Immunocytochemistry staining 
After fixation with 4 % paraformaldehyde for 30 min at room temperature, cells were 
incubated for 30 min in a 50 % goat serum solution containing 1 % BSA and 100 mM L-
lysine to block nonspecific binding and 0.4 % Triton X-100 to permeabilized the membrane. 
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To stain the somatotropes, cultures of anterior pituitary gland were incubated in polyclonal 
anti-porcine GH antibody (dilution 1:50,000). Antibody visualization was accomplished by 
using a Vectastain ABC kit (Vector) and the nickel-enhanced 3-3' diaminobenzidine method 
[20]. 
Intracellular calcium imaging 
The effect of secretagogues on intracellular calcium concentrations [Ca+2 ], was evaluated by 
ratiometric imaging techniques [21]. Cells were loaded with Fura 2-AM for 40-60 min at 37 
°C. 1 fj.1 of 25 % (w/w) of Pluronic F-127 was mixed with 4 nM of AM ester to aid 
solubilization of the ester into aqueous medium. Coverslips containing pituitary cells were 
washed with HEPES-buffered solution and further incubated for 10 min at 37 °C to allowed 
deesterification of Fura 2-AM. All image processing and analysis were performed using an 
Attoflour system (Atto Bioscience) with Zeiss microscope. Background subtraction and ratio 
images were used to calculate the [Ca+2]; according to Equation 5 of Grynkiewitz et al. [22]. 
Using wavelengths of 340 and 380 nm, Fura 2-AM was excited and the emitted light was 
analyzed at 520 nm. 
Statistical analysis 
For every treatment, sister cultures were used as controls in order to minimize the effect of 
variability in individual response. Data are shown as the mean ± S.E.M for at least two 
independent experiments. Simple comparisons between two groups were made by Student's 
t test. Multiple comparisons were carried out by one-way analysis of variance (ANOVA) 
followed by Newman-Keuls Multiple Comparison Test. Differences were considered as 
statistically significant at P < 0.05. 
Results 
Stimulatory effect of ghrelin on [Ca2+]i in cultured porcine somaototropes 
Presence of somatotropes in pituitary cell cultures was confirmed by immunocytochemical 
staining with antibody raised against GH. GH immunoreactive cells comprised 40 % of the 
total pituitary cells in cultures. Increase in [Ca2+]; above the baseline following hGHRH 
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application functionally identified GH cells. Perfusion with hGHRH (10 jjM) for 2 min 
increased [Ca2+]; in somatotropes by 55 ± 3.0 nM (mean ± SEM; n = 232; P < 0.01; Fig. 1A). 
Of the cells that responded to hGHRH, 98 % also responded to 1 p,M ghrelin applied 10 min 
after the application of hGHRH. Perfusion application of 1 pM ghrelin for 2 min produced a 
prompt transient increase in [Ca2+]; of 57 ± 3.0 nM (n = 227; P < 0.01; Fig. 1A), followed by 
the sustained decline to a plateau above the basal level. Similar calcium response was 
observed in previous work after treatment of isolated porcine somatotropes with nonpeptidyl 
GHS, L-692,585 (L-585) [23]. Experiments where reverse hemolytic plaque assay (RHPA) 
and [Ca2+]; measurements were done concurrently demonstrated that calcium transient in 
cultured pituitary cells after application of L-585 coincided with GH secretion, implying that 
calcium transient evoked by ghrelin is also followed by GH release. 
Plateau response was consistently observed after ghrelin application and was present 
even 30 min after application of ghrelin (Fig. 1A), suggesting that plateau was not result of 
incomplete washing of agonist or an artificial change in basal [Ca2+];. When ghrelin was 
applied twice within 10 min, the second application of ghrelin, caused an increase in [Ca2+]; 
in only 34 % of the cells that responded to the first application. The second application of 1 
(j,M ghrelin, 30 min after the first application increased [Ca2+]j in 75 % of the cells that 
responded to the first application (Fig. 1A). A second application of ghrelin (1 pM^ during 
the plateau effect of the first application, did not have an additive effect on the increase in 
[Ca2+]; (Fig. 1 A). Application of the nonselective stimulus, potassium (50 mM), after hGHRH 
and ghrelin, resulted in elevated [Ca2+];by 93 ± 6.2 nM (P < 0.01) in all cells that responded 
to hGHRH and ghrelin (Fig. 1 A). 
The effect of ghrelin on calcium transient in cultured porcine somatotropes was dose 
dependent (Fig. IB). In parallel run cultures, application of 500 nM ghrelin for 2 min elicited 
significantly bigger increase in [Ca2+]; than 100 nM ghrelin (42 ±3.1 nM, n = 64 vs 31 ± 2.0 
nM, n = 57 nM; P < 0.05), while after the application of 1 (J.M ghrelin average rise of 
intracellular Ca2+ concentration (65 ± 3.4 nM; n = 100) was significantly bigger (P < 0.01) 
than response after application of 500 and 100 nM ghrelin. 
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To study possible interactions between GHRH and ghrelin, we determined responses 
of somatotropes to lower concentrations of ligands. Application of 5 |iM hGHRH increased 
[Ca2+]; by 30.1 ±1.7 nM (n = 100; P < 0.01; Fig. 2A) and subsequent application of 500 nM 
ghrelin increased [Ca2+]; by 40 + 3.1 (n = 68; P < 0.01; Fig. 2A). As shown in Fig 2B, 
simultaneous application of 5 |iM hGHRH and 500 nM ghrelin for 2 min produced a 
significant increase in [Ca2+]j (35 ± 1.9 nM; n = 110; P < 0.01) but did not have an additive 
effect on the increase in [Ca2+];. 
Receptor mediation of stimulatory effect of ghrelin on [Ca2+]; 
To determine whether the effect of ghrelin was receptor mediated, experiments were 
performed with (D-Lys3)-GHRP-6, a specific antagonist of GHS-R [6]. Perfusion of cultures 
with 100 pM (D-Lys3)-GHRP-6 for 10 min before ghrelin, decreased [Ca2+]; from 91 ±4.8 
nM to 64 ± 2.8 nM (n = 101; P < 0.01; Fig. 3B). In the presence of (D-Lys3)-GHRP-6, the 
increase in [Ca2+]; evoked by ghrelin (1 |-iM) was delayed for about 100 sec and decreased 
compared to response in controls (81 ± 4.7, n - 92 vs 65 ± 4.0 nM, n - 80; P < 0.05; Fig. 
3A,B). In control cultures 98 % of cells (92 of 94) that responded to hGHRH responded to 
ghrelin, while after pretreatment of cultures with (D-Lys3)-GHRP-6, only 79 % of cells (80 of 
101) that responded to hGHRH responded to ghrelin. These results support the GHS-R 
mediating the effect of ghrelin increasing [Ca2+]; in cultured porcine somatotropes. 
Somatostatin (SRIH) decreases effect of ghrelin 
Application of SRIH at concentrations of 10 |a,M decreased intracellular calcium levels from 
92 ± 3.5 nM to 69 ± 2.5 nM (n = 115; P < 0.01; Fig. 3C). After pretreatment of the cultures 
with 10 (0.M SRIH for 10 min, 90 % of cells that responded to 10 |_iM hGHRH responded to 1 
|o.M ghrelin (103 of 115). In parallel run controls, a similar percent of cells that responded to 
application of hGHRH responded to ghrelin (93 %). In the presence of 10 |a,M SRIH, the 
increase in [Ca2+]; evoked by perfusion application of 1 |j,M ghrelin for 2 min was decreased 
(78 ± 4.1 nM, n = 121 vs 48 ± 2.7 nM,«= 103; P < 0.01; Fig. 3A,C). 
79 
Neuropeptide Y (NPY) decreases effect of ghrelin 
NPY has a role in regulation of GH secretion [24, 25, 26] and thus the ability of ghrelin to 
evoke changes in [Ca2+]; in the presence of NPY was examined. Treatment of somatotropes 
with NPY (1 (j,M) for 10 min decreased [Ca2+]; from 98 ± 2.4 nM to 77 ± 1.7 nM (n = 144; P 
< 0.01; Fig. 3D). In the presence of NPY, the increase in [Ca2+]; evoked by 1 |aM ghrelin for 2 
min was decreased compared to response in the control cultures (63 ± 3.5 nM, n = 140 w 39 
±2.1 nM, n = 128; P < 0.01: Fig. 3A,D). Thus NPY influenced the stimulatory effects of 
ghrelin. 
Role of membrane depolarization and calcium channels in ghrelin effects 
To investigate the requirement of extracellular calcium for hGHRH and L-585 induced 
calcium transients in cultured somatotropes, cells were bathed in calcium depleted HEPES 
with the addition of 1 mM EGTA to yield an extracellular free calcium level of 26 nM. It was 
necessary to have some calcium in the bathing medium, otherwise the cells detached from the 
culture substrate. The stimulatory effect of ghrelin was significantly decreased in calcium 
depleted saline (Fig. 4A,B). In low Ca2+ HEPES, only 42 % of the cells that responded to 
hGHRH also responded to ghrelin. The amplitude of ghrelin-evoked transient increase in 
[Ca2+]; in low calcium HEPES was significantly smaller than in normal Ca2+ HEPES (65 ± 
2.6, n = 200 nM vs 29 ± 1.7 nM, n = 76; P < 0.01), and the second, sustained phase of 
calcium increase was abolished (Fig. 4B). These results suggest that extracellular calcium has 
an important role in the effect of ghrelin on GH secretory cells. 
To investigate the contribution of voltage dependent Ca2+ channels in calcium influx 
evoked by ghrelin, experiments were performed in the presence of nifedipine, an antagonist 
of the L-type calcium channel. In control cultures, ghrelin (1 (J.M) evoked a response in all 
cells (n = 139) that first responded to the hGHRH (10 p.M). In the presence of 100 nM 
nifedipine, 1 jj,M ghrelin evoked a response in 90 % of the cells (64 of 71) that responded to 
hGHRH. The average increase in [Ca2+], was significantly smaller (60 ± 2.4 v-s 39 ± 2.2 nM; 
P < 0.01; Fig. 4A,C) and the duration of the sustained phase of calcium increase was brief. 
Application of 50 mM K+, 10 min after ghrelin, resulted with significantly smaller increase in 
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[Ca2+]j in the presence of nifedipine (112 + 11.4 nM, n - 139 vs 48 ± 6.3 nM, n - 71; P < 
0.01; Fig. 4A,C). 
To determine the role of Na+ in ghrelin-induced changes in [Ca2,]„ cultures were 
bathed in zero Na+ solution (sodium was replaced with choline). In zero Na+ HEPES, only 74 
% of the somatotropes (88 of 119) responded to ghrelin (1 pM) compared to 100% in normal 
HEPES solution. The amplitude of the increase in [Ca2+], evoked by ghrelin was smaller 
compared to that in normal sodium concentration (73 ± 7 nM vs 27+2 nM, P < 0.01; Fig. 
4A,D). 
Signal transduction pathways, phospholipase C (PLC), and adenylyl cyclase - cyclic 
adenosine 3,5-monophosphate (AC-cAMP), are activated by ghrelin 
Results with the application of ghrelin in deplated Ca2+ solution suggested that in ghrelin 
induced GH secretion, extracellular Ca2+ has an important role but that intracellular Ca2+ has 
some role, too. The involvement of intracellular Ca2+ stores ghrelin action was further 
investigated in experiments with U73122, a selective inhibitor of phospholipase C (PLC) 
[27]. Pretreatment of cultures for 10 min wuth 5 |a,M U73122 significantly decreased the 
effect of 1 |xM ghrelin on calcium transient (65 ± 2.9 nM, n = 82 vs 44 ± 2.1 nM, n = 73; P < 
0.01; Fig. 5A,B), implying an involvement of the PLC-IP3 pathway in the ghrelin action. 
To determine whether ghrelin activates cyclic adenosine 3,5-monophosphate pathway, cell 
cultures were pretreated with SQ-22536, an adenylyl cyclase inhibitor [28]. After 10 min 
application of SQ-22536 in concentrations 100 (j,M, the amplitude of [Ca2+]s increase evoked 
by 1 p,M ghrelin was significantly decreased (60 + 2.4, n = 139 vs 47 ±1.8, n = 80; P < 0.01; 
Fig. 5A,C), suggesting activation of AC by ghrelin. 
Interactions between ghrelin and L-585 on calcium transient in porcine somatotropes: 
potential antagonism 
Previously, we have demonstrated a stimulatory effect of L-585 on porcine somatotropes 
[23]. To investigate interaction between ghrelin, an endogenous GHS, and L-585, on calcium 
transients in cultured porcine somatotropes, these were applied in succession or 
simultaneously. The application of L-585 (10 |iM) for 2 min produced a prompt increase in 
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[Ca2+];, followed by plateau phase (54 ± 3.5; n = 97; Fig. 6A). When L-585 (10 p.M) was 
applied 10 min after the application of 1 pM ghrelin, it did not have an additive effect on 
[Ca2+]j (33 ± 2.3; n = 101; P<0.01; Fig. 6A,B). The effects of lower doses of ghrelin were 
examined. At 100 nM, ghrelin per se did not have influence on [Ca2+]j. In the presence of 
this concentration of ghrelin, applied 5 min before L-585, the average increase in [Ca2+]; 
evoked by L-585 was greatly attenuated (39 ± 3.9 nM, n = 34 vs 24 ± 3.4 nM, n = 19; P < 
0.05; Fig. 6C). In control cultures, all cells that responded to hGHRH also responded to L-
585, whereas after pretreatment of cultures with 100 nM ghrelin only 27 % of somatotropes 
(19 of 70) responded to L-585. When ghrelin (1 |j,M) was applied during the plateau phase of 
L-585-induced increase in [Ca2+]; (10 min after 10 jaM L- 585), the stimulatory effect of 
ghrelin was blocked and there was an unexpected decrease of [Ca2+]; from 125 ± 2.9 nM to 
108 ± 2.7 nM (n = 80; P < 0.01; Fig. 7A,B). 
To determine whether the ghrelin response was blocked because it was applied during 
the plateau phase of L-585 action, we applied ghrelin after elevation of [Ca2+]; in porcine 
somatotropes by 10 mM K+. Under such conditions the application of ghrelin resulted first 
with a prompt calcium increase that was followed by a sudden decrease in [Ca2+]j (Fig. 7C). 
Combined treatment with the two GHS, ghrelin and L-585 did not have an additive 
effect on [Ca2+];. These data are summarized in Table 1. Applied simultaneously, 10 jaM L-
585 and 1 |a,M ghrelin produced an uncharacteristic brief increase in [Ca2+]; without the 
typical prolonged plateau phase (Fig. 7D). The increase in [Ca2+]j was not additive but, in 
fact, was lower (P < 0.05) than those evoked by either 10 jaM L-585 or 1 jjM ghrelin alone 
(Table 1). Similarly, simultaneous application of lower doses L-585 (5 |iM) and ghrelin (500 
nM) did not have an additive effect on [Ca2+]j (Table 1). Indeed in the presence of ghrelin, the 
L-585 evoked increase in [Ca2+]; was less that observed with L-585 alone. These results 
suggest that ghrelin and L-585 may compete, probably at the receptor levels, with ghrelin 
acting ^s a partial antagonist. 
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Discussion 
Studies in our laboratory have demonstrated that porcine somatotropes have a regulated 
secretory pathway in which secretory vesicles fuse with the plasma membrane in response to 
stimulus such as GHRH or L-585 [29]. In the present study, we have shown that ghrelin has a 
direct, dose dependent, stimulatory effect on [Ca2+]; in isolated porcine somatotropes. It is 
presumed that this increase in [Ca2+]; evoked by ghrelin is followed by GH release [30]. 
Secretion of GH from perifused rat anterior pituitary cells reached a maximum 2 min after 
ghrelin application [31]. This coincides temporally with peak increase in [Ca2+]j evoked by 
ghrelin in our experiments, suggesting calcium involvement in the GH release evoked by 
ghrelin. Similarly, in previous experiments on isolated porcine somatotropes with 
simultaneous measurements of GH release and calcium transients we have shown that L-585, 
a nonpeptidyl GHS, evoked an increase in [Ca2+];that coincided with GH release [23]. An 
increase in [Ca2+]; was observed with ghrelin in all cells that responded to hGHRH. It may be 
questioned whether these act via the same signal transduction pathway. 
The amplitude of increase in [Ca2+]s evoked by ghrelin was similar to that with 
hGHRH with the latter at the 10-fold greater concentration. This may suggest that ghrelin is 
more potent than GHRH in stimulating rapid release of GH. In human studies, it is shown 
that the potency of ghrelin for GH release is similar to those of GHS, but greater than GHRH, 
indicating a distinctive pharmacological action [15, 16]. However, in rat anterior pituitary 
cells ghrelin caused weaker GH secretion than GHRH [31], suggesting that potency of 
ghrelin is species-dependent. There was no evidence for any heterologous desensitization 
between hGHRH and ghrelin. However, homologous desensitization was observed with 
repeated application of ghrelin. Repeated application of ghrelin after 10 and 30 min evoked a 
response in 34% and 75% of cells that responded to the first application. Previous studies 
have shown that there is no cross-desensitization between GHRH and GHS in GH release, 
while homologous desensitization does occur [2, 32]. Release of GH from dispersed rat 
pituitary cells was decreased after serial ghrelin stimulation at 1 h intervals, also indicating 
that it strongly desensitized somatotropes [31]. 
At low doses ghrelin synergizes with GHRH on GH secretion from the human 
pituitary gland. This also suggests different sites of action for these secretagogues [16, 17]. 
83 
Simultaneous application of hGHRH and ghrelin in the present study, however, did not have 
an additive effect on intracellular calcium concentration in cultured porcine somatotropes. In 
agreement with our results, stimulation with ghrelin and GHRH did not elicit either a 
synergistic or an additive GH response from the dispersed rat pituitaiy cells [31], suggesting 
that ghrelin indirectly affects GH release from pituitary gland via hypothalamic mediators. In 
previous study [23] simultaneous application of GHRH and L-585 also did not have an 
additive effect on calcium increase in porcine somatotropes, implying that hypothalamus is 
important sight of action of both endogenous and exogenous GHS and that for their maximal 
effect an intact hypothalamo-pituitary axis is necessary. 
To investigate whether the stimulatory effect of ghrelin on [Ca2+], in porcine 
somatotropes is mediated by the GHS-R, we used, a putative competitive GHS-R antagonist, 
(D-Lys3)-GHRP-6 [6], The stimulatory effect of ghrelin in the presence of used (D-Lys3)-
GHRP-6 was considerably decreased. This supports the mediation by GHS-R of ghrelin's 
effect on calcium transient in porcine somatotropes. While (D-Lys3)-GHRP-6 failed to 
completely depress the increase in [Ca2+]; evoked by ghrelin, this can be explained by a lower 
affinity of (D-Lys3)-GHRP-6 for GHS-R compared to that of ghrelin [9, 33]. In CHO-
GHSR62 cells, in the presence of 10"4 M (D-Lys3)-GHRP-6, [Ca2+]; increase evoked by lower 
doses of ghrelin was depressed, but not in the presence of a high dose of ghrelin, indicating 
that ghrelin is competitively inhibited by the antagonist [9]. It is also possible that several 
subtypes of GHS-R exist [34, 35]. 
Somatostatin decreased, but did not abolish the effect of ghrelin on calcium transient 
in porcine somatotropes. In our previous study with L-585, SRIH was also more effective in 
suppressing the stimulatory effect of hGHRH compared to L-585 [23]. SRIH alone decreased 
[Ca2+]j. The effects of SRIH on somatotropes are mediated either by inhibiting of cAMP 
formation [36] or via decreased Ca2+ influx as a result of an increase in K+ conductance and 
hyperpolarization of somatotropes [37]. GHSs, and probably ghrelin, can behave as 
functional SRIH antagonists by inhibiting K+ channels and depolarizing the plasma 
membrane of the somatotropes [38]. 
It has been suggested that NPY suppresses the release of GH by reciprocal regulation 
of GHRH and SRIH neurons [39]. Indeed, centrally administered NPY inhibited GH 
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secretion in rats [24, 26] and pigs [41]. In the present study, pretreatment of cultured porcine 
pituitary cells with NPY decreased the effect of ghrelin on [Ca2+];. Direct inhibitory effects of 
NPY on GH secretion have been observed with human pituitary somatotropic tumours in cell 
culture with reductions of GHRH stimulatory effects by NPY [25]. Our results, supported by 
those with human tumor cells, clearly demonstrate that NPY can inhibit GH secretion also by 
suppressing the ghrelin stimulatory effect on the somatotrope directly. In addition, NPY 
decreased basal [Ca2+]j. It is possible that NPY, similar to the situation with SRIH, exerts its 
inhibitory effect on ghrelin by modulating [Ca2+];-
Depletion of extracellular calcium greatly diminished but did not completely abolish 
the stimulatory effect of ghrelin on porcine somatotropes. The latter suggests that while 
ghrelin does mobilize Ca2+ from intracellular stores, Ca2+ influx has the major contribution to 
calcium transient. In somatotropes, the major Ca2+ channels are the voltage-gated T- and L-
types [41]. Perfusion of porcine cells with nifedipine decreased the effect of ghrelin. This 
indicates an involvement of L-type Ca2+ channels in calcium influx induced by ghrelin, and 
that influx of calcium is a crucial step in the action of ghrelin, as in the action of L-585 [23]. 
The stimulatory effect of ghrelin was decreased in a zero Na+ environment, suggesting 
that ghrelin can depolarize somatotropes at least, partially, through sodium channels. 
Potassium channels may also be involved in the action of ghrelin, because activation of GHS-
R leads to inhibition of K+ channels, allowing the entry of Ca2+ through voltage-gated 
channels [2, 38]. In addition, different second messengers can activate calcium channels. 
Cyclic adenosine monophosphate (cAMP), protein kinase A and C, and phospholipase C are 
possible signaling systems involved in the action of GHS [34, 38], and are likely involved in 
the ghrelin action. In our experiments U73122, a PLC inhibitor, decreased the effect of 
ghrelin on calcium transient, indicating the involvement of PLC/IP3 pathway in ghrelin action 
on porcine somatotropes. Pretreatment of porcine somatotropes with SQ-22536, an adenylyl 
cyclase inhibitor, also decreased the stimulatory effect of ghrelin on calcium transient, 
implying that the binding of ghrelin to GHS-R activates adenylyl cyclase. Our results 
indicated that the first phase of ghrelin-evoked calcium increase resulted from intracellular 
Ca2+ mobilization, whereas the second phase represents calcium influx. In low calcium 
HEPES or with nifedipine or in zero sodium HEPES, this second sustained phase was almost 
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completely abolished. Very similar results and conclusions were drawn from studies 
examining the ability of L-585 to affect [Ca2+]; in low calcium HEPES or with nifedipine or 
in zero sodium HEPES in porcine somatotropes [23]. This suggested that ghrelin and L-585 
possess similar mechanisms of action. The commonalty in action between ghrelin and 
peptidyl GHS has been previously shown. The endocrine responses to ghrelin were not 
modified by the coadministration of hexarelin [16]. After repeated administration of ghrelin 
or GHRP-2, desensitization of the GH response was induced by the homologous agent, and 
also by the heterologous agent in crossover studies with the two peptides [18]. 
In the present study, we have for the first time investigated interactions between 
ghrelin and the nonpeptidyl GHS, L-585. To examine interactions between ghrelin and L-
585, we either applied these agonists in succession or simultaneously. L-585 had no additive 
effect on [Ca2+]j when applied 10 min after ghrelin (that is during the plateau increase in 
[Ca2+]j ). Moreover, the response evoked by L-585 was almost completely abolished when 
applied in the presence of 100 nM ghrelin; a concentration that alone did not have any effect 
on [Ca2+];. The stimulatory effect of ghrelin was blocked when it was applied during the 
plateau phase of L-585 action, and instead of an increase, an abrupt decrease in [Ca2+]f 
occurred. Similar decrease in [Ca2+]; was detected when ghrelin was applied during the 
plateau increase induced by 10 mM K+. 
Simultaneous application of ghrelin and L-585 did not have additive effect on 
calcium transient. Indeed the change in [Ca2+], was reduced compared to either GHS alone. 
Together our experiments with ghrelin and L-585 indicate antagonistic effects between these 
two agonists. Competition between ghrelin and L-585 probably occurs at the GHS-R on 
somatotropes, which may involve binding to the different but overlapping domains on the 
same receptor. Alternatively, competition between these agonists may occur downstream 
from the GHS-R or sub-types. 
In summary, ghrelin has a direct stimulatory effect on porcine somatotropes. During 
the first phase of the ghrelin-induced calcium transient activation of different signal 
transduction pathways result with calcium mobilization from internal stores, whereas a 
second prolonged phase results from calcium influx as a consequence of somatotrope 
depolarization by ghrelin acting on Na+ and K+ channels and the activation of calcium 
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channels by acting on different second messengers. Similar responses were previously 
obtained with L-585 suggesting a similar mechanism of action between ghrelin and 
nonpeptidyl GHS. Unexpectedly, there were antagonistic effects of ghrelin and L-585 on 
calcium transients in porcine somatotropes. The basis for these is unknown but they do not 
appear to represent simple competitive antagonism. 
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Table 1. Effect of ghrelin and L-585, alone and together, on changes in [Ca2+]; in pig 
somatotropes. 
Treatment Concentration 
(pM) 
Increase in [Ca2+]; (nM) 
± S.E.M. (n=) 
Ghrelin 0.5 34 ± 7.0 (26)ab 
L-585 5 49 ± 5.5 (44)' 
Ghrelin + L-585 0.5 + 5 29 ±5.0 (31)" 
Ghrelin 1 62 ± 8.4 (22)' 
L-585 10 65 ± 8.1 (22)" 
Ghrelin + L-585 1 + 10 32 ± 3.5 (32)" 
Different superscript numbers indicate difference, P < 0.05 
Figure 1. Stimulatory effect of ghrelin on [Ca2+]j in porcine somatotropes: 
A) The sequence of pseudocolor images and kinetics of the [Ca2+]j changes illustrate 
response of isolated porcine pituitary cells to application of 10 jxM hGHRH, two 
consecutive applications of 1 pM ghrelin, and 50 mM K+ (n = 22). Somatotropes were 
functional identified by 2 min application of 10 p,M hGHRH. Subsequent administration 
of 1 |j,M ghrelin evoked increase in [Ca2+]i in 98% of somatotropes. The repeated 
administration of ghrelin after 30 min did not have additive effect on the [Ca2+]j increase, 
suggesting existence of homologous desensitization of GHS receptors. Application of 50 
mM K+ increased [Ca2+]i in all cells that responded to hGHRH and ghrelin. Panels of 
images of calcium transient were taken at the time indicated on time course histogram. 
B) Application of ghrelin in concentrations of 100 nM, 500 nM and ljxM, dose-
dependently increased [Ca2+]j in isolated porcine somatotropes. The application of 500 
nM ghrelin for 2 min evoked a smaller response than application of 1 pM ghrelin in 
cultures run in parallel (P < 0.01), while the application of 100 nM ghrelin for 2 min 
evoked a smaller response than application of 500 nM ghrelin in cultures run in parallel 
(P < 0.05). 
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Figure 2. Simultaneous application of hGHRH and ghrelin did not have an additive effect 
on calcium transient: 
A) Increase in [Ca2+]; after 2 min application of hGHRH (5 p.M) and ghrelin (500 nM) (n 
= 21) 
B) Increase in [Ca2+]; after simultaneous application of hGHRH (5 |iM) and ghrelin (500 
nM) for 2 min, was not significantly different from response elicited by eider agonist 
alone (n = 28). 
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Figure 3. Inhibitory effects of (D-Lys3)-GHRP-6, SRIH and NPY on calcium transient 
evoked by 2 min application of 1 pM ghrelin: 
A) Increase in [Ca2+]; after sequential application of hGHRH (10 |J-M), ghrelin (1 p,M) and 50 
mM K+ (n = 27). 
B) Pretreatment of cultures for 10 min with (D-Lys3)-GHRP-6 (100 juM) decreased [Ca2+]i; 
and attenuated the response evoked by ghrelin (1 p.M) (n = 42; P < 0.05), suggesting that 
stimulatory effect of ghrelin is mediated through GHS-R. 
C) Application of SRIH (10 pM) for 10 min decreased [Ca2+]; and reduced the response to 
ghrelin (1 p,M) (n = 37; P< 0.01). 
D) Pretreatment of cultures for 10 min with NPY (1 |iM) decreased both [Ca2+]f and the 
increase_in [Ca24]; evoked by ghrelin (1 |_iM) (n = 21; P < 0.01). 
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Figure 4. Calcium and sodium channels are involved in ghrelin induced calcium transient in 
isolated porcine somatotropes: 
A) Effects of hGHRH (10 |-iM), ghrelin (1 pM), and 50 mM K+ on calcium transient in 
isolated porcine somatotropes (n = 26). 
B) Bathing the cultures in low Ca2+ solution decreased baseline [Ca2+]j and dramatically 
reduced the stimulatory effect of ghrelin (1 jaM) on [Ca2+], in isolated porcine somatotropes 
(n = 22; P < 0.01). 
C) Perfusion of culture with nifedipine (100 nM), a blocker of L-type Ca channels, decreased 
stimulatory effect of ghrelin (1 p,M) (P < 0.05) and 50 mM K+ on isolated porcine 
somatotropes (n = 19; P < 0.01). 
D) Removing of Na+ ions from the bathing solution decreased the effect of IjjM ghrelin on 
calcium transient (n = 18; P < 0.01). 
Figure 5. PLC-IP3 and AC-cAMP pathways are involved in stimulatory effect of ghrelin 
on cultured porcine somatotropes: 
A) Control effect of 10 jiM hGHRH, 1 pM ghrelin, and 50 mM K+ on calcium transient 
in isolated porcine somatotropes (n = 33). 
B) Pretreatment of the cultured porcine pituitary cells with 5 (J.M U73122 decreased the 
stimulatory effect of ghrelin (P < 0.01; n = 24). 
C) in the presence of 100 |aM SQ-22536 (SQ), adenylyl cyclase inhibitor, stimulatory 
effect of ghrelin was decreased (P < 0.01; n = 25). 
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Figure 6. Inhibitory effects of ghrelin on calcium transients evoked by L-585 in isolated 
porcine somatotropes: 
A) Control studies on calcium transients in isolated porcine somatotropes evoked by 2 
min application of hGHRH (10 pM) and L-585 (10 pM) (n = 29). 
B) Application of L-585 (10 pM), 10 min after application of ghrelin (1 pM), did not 
have an additive effect on [Ca2+]i in isolated porcine somatotropes (n = 58). 
C) Ghrelin (100 nM), alone did not affect [Ca2+]i, but the changes in [Ca2+]i evoked by 10 
|iM L-585 was almost completely blocked (n = 7). 
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Figure 7. Inhibitory effect of L-585 on calcium transient evoked by ghrelin in isolated 
porcine somatotropes: 
A) Control effect of 10 jaM hGHRH and 1 |iM ghrelin on calcium transient in isolated 
porcine somatotropes (n = 20). 
B) Stimulatory effect of 1 |iM ghrelin on calcium transient in isolated porcine 
somatotropes was blocked when ghrelin was applied during the plateau phase of calcium 
increase evoked by L-585. Instead of increase in [Ca2+]i, application of ghrelin produced 
sudden drop in [Ca2+]j (n = 21). 
C) Application of 1 jo,M ghrelin for 2 min during the plateau phase of [Ca2+]j increase 
evoked by perfusion application of 10 mM K+ produced prompt increase in [Ca2+]j 
followed by sudden drop in [Ca2+]j (n = 46). 
D) Simultaneous application of 10 |iM L-585 and 1 (J.M ghrelin for 2 min produced a 
uncharacteristic, brief and not additive effect on the [Ca2+]j increase (n = 26). 
102 
240 
220 
200 
sr 180 
-r 
160 
<N 
u 140 
120 
100 
80 
0 200 400 600 800 1000 1200 1400 1600 
}ŒZZX Time (sec) 
hGHRH lOgM Ghrelin IjiM 
0 200 400 600 800 1000 1200 1400 1600 
I I V77A Time (sec) 
hGHRH IOjjM L-585 lO^iM Ghrelin IpM 
10 mMK 
D 
0 200 400 600 800 1000 1200 1400 1600 
xzzzi Time (sec) 
hGHRH lOuM Ghrelin l|iM 
240 
220 
200 
£ 180 
-r 
160 
<N 
u 
140 
120 
100 
80 
200 400 600 800 1000 1200 1400 1600 
'tzi 
hGHRH lOuM L-585 lO^M + Ghrelin lpM 
Time (sec) 
103 
CHAPTER 5. GENERAL CONCLUSIONS 
This dissertation presents the results of investigation the sites and cellular 
mechanisms of action of an exogenous, nonpeptidyl GH secretagogue - L-585, and 
endogenous GH secretagogue - ghrelin, on cultured porcine somatotropes. Understanding of 
the role of GHS in hypothalamic-pituitary axis has been increasing in recent years. This 
research contributes to this body of knowledge by showing that both, exogenous and 
endogenous GHS have direct stimulatory effect on [Ca2+]; in cultured porcine somatotropes, 
that is followed by release of GH. These results strongly suggest that GHS are indeed 
physiological regulator of GH secretion. 
General summary 
In the first study, the cellular mechanism of action of L-585 on isolated porcine 
somatotropes was investigated. ICC using antibody against GH confirmed the presence of 
somatotropes in porcine pituitary cultures. The ability of L-585 to stimulate Ca2+ transients 
and GH secretion from cultured porcine somatotropes was tested. All cells, that were 
identified as somatotropes by increase in [Ca2+]; after hGHRH application, responded also to 
perfusion application of L-585. Application of 10 p,M L-585 for 2 min evoked prompt 
transient in [Ca2+]; followed by sustained decline to a plateau above the basal level. In 
experiments where RHPA and [Ca2+], measurements were done concurrently, it was shown 
that increase in [Ca2+]; evoked by L-585 coincides with GH secretion. Incubation of cultured 
cells with L-585 for 3 h resulted with increased number and size of plaques around 
somatotropes, showing stimulatory effect of L-585 on GH secretion. Simultaneous 
application of L-585 and hGHRH did not have an additive effect on [Ca2+]h hGHRH and L-
585 exert their stimulatory effect on [Ca2+]; in porcine somatotropes through different 
receptors, since SP analogue and GHRH receptor antagonist, influenced just effect of 
hGHRH. The depletion of calcium from bathing medium and blocking of L-calcium channels 
by nifedipine decreased initial peak increase and abolished the plateau component of L-585-
induced calcium changes, suggesting involvement of extracellular calcium. Both adenylyl 
cyclase (AC) inhibitor (SQ-22536), and PLC inhibitor (U73122), significantly decreased 
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stimulatory effect of L-585, implying that L-585 mobilizes Ca2+ from internal stores by the 
activation of AC-cAMP and PLC- inositol 1,4,5-trisphosphate pathways (IP3). These results 
together suggest that rapid increase in [Ca2+]; induced by L-585 originated from the 
intracellular stores, while the plateau phase resulted from somatotropes depolarization and 
extracellular calcium entry. 
In the second study plasma membrane structures involved in GH secretion from 
isolated porcine somatotropes were observed using AFM. Recently, new group of plasma 
membrane structures, named 'pits' and 'depressions', were found on apical membrane of 
pancreatic acinar cells. It was demonstrated that structures are sites at plasma membrane 
where vesicles dock and fuse to release content. In this study, the same structures were 
observed at the plasma membrane of somatotropes. On the plasma membrane of resting 
somatotropes were found 'pits' containing several 'depressions', or fusion pores, with 
diameter of 100-200 nm. After stimulation of cultured porcine somatotropes with 
nonpeptidyl GHS - L-585, enlargement of 'depressions' for about 40 % was observed. When 
cells stimulated with L-585 were fixed and later exposed to 30 nm gold-tagged GH-antibody, 
fusion pores were lost due to large amounts of gold-tagged antibody binding at these sites. 
These results together have shown that 'depressions' are structures at plasma membrane of 
somatotropes involved in hormone secretion. The existence of 'pits' and 'depressions' both 
in exocrine and neuroendocrine cells imply that these structures may be common for all 
secretory cells. 
The effect of ghrelin, an endogenous ligand for GHS-R, on intracellular Ca2+ 
concentration in isolated porcine somatotropes was investigated in the third study using a 
calcium imaging system. Somatotropes were functionally identified by application of 
hGHRH. Subsequent application of 1 pM ghrelin increased [Ca2+]s in 98 % of the cells that 
responded to hGHRH. Repeated application of 1 pM ghrelin after 10 and 30-min increased 
[Ca2+]j in 34% and 75% of cells that responded to the first application, suggesting that 
homologue desensitization of GHS-R occurred. Effect of ghrelin on somatotropes was doze 
dependent. Ghrelin in concentration of 100 and 500 produced significantly smaller response 
than 1 (j,M ghrelin. Similar to the results observed with synthetic GHS, simultaneous 
application of ghrelin and hGHRH did not cause an additive increase in [Ca2+];. The 
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stimulatory effect of ghrelin on somatotropes was receptor mediated and it was decreased in 
the presence of (D-Lys3)-GHRP-6, a specific receptor antagonist of GHS-R. Ghrelin-induced 
increase of [Ca2+]; was reduced in the presence of SS and NPY. The experiments in low 
calcium saline and with L-calcium channel blocker - nifedipine have shown that influx of 
calcium through calcium voltage dependent channels is involved in calcium increase evoked 
by ghrelin. The sodium channels are also involved in ghrelin-induced calcium a transient as 
was shown by experiments in a zero Na+ solution. Pretreatment of cultures with adenylyl 
cyclase (AC) inhibitor (SQ-22536), and PLC inhibitor (U73122), significantly decreased 
stimulatory effect of ghrelin, implying that activation of AC-cAMP and PLC- inositol 1,4,5-
trisphosphate pathways (IP3) were involved in ghrelin evoked calcium mobilization from 
internal stores. These results together suggested that rapid increase in [Ca2+]f induced by L-
585 originated from the intracellular stores, while the plateau phase resulted from 
somatotropes depolarization and extracellular calcium entry. The application of nonpeptidyl 
GHS, L-585 resulted with changes in [Ca2+]; similar to those induced by ghrelin. When L-585 
was applied 10 min after the application of ghrelin, it did not cause an additive increase in 
[Ca2+];. Pre-application of the low dose of ghrelin, that alone did not influence the [Ca2+];., 
greatly attenuated the stimulatory effect of subsequently applied L-585. Application of 
ghrelin, 10 min after the application of L-585, resulted with an unexpected decrease in 
[Ca2+]j. Simultaneous application of ghrelin and L-585 did not have an additive effect on 
[Ca2+]; increase, but resulted with reduced change in [Ca2+]; compared to either GHS alone. 
Our results suggest that the action of ghrelin and synthetic GHS closely parallel each other, 
and that antagonistic effects between these two agonists may result from competition at the 
receptor level and/or downstream from GHS-R. 
General discussion 
The central regulation of pituitary GH release is mediated by opposing actions of two 
hypothalamic hormones, GHRH and SS (Frohman et al. 1992, Muller et al. 1999). In 
addition, synthetic GHS exhibit strong GH-releasing activity by acting both on the pituitary 
and hypothalamus, where GHS-R are present (Dickson et al. 1995, Smith et al. 1996, 
Casanueva & Dieguez 1999). In fact, an endogenous ligand for GHS-R, ghrelin, was 
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discovered and specifically stimulated GH secretion both in vitro and in vivo (Kojima et al. 
1999). Thus, ghrelin is thought to be the third physiological regulator of GH secretion. 
Although the effects of various non-peptidyl GHS on GH secretion in pigs have been 
analyzed in several studies in vivo (Chang et al. 1995, 1996, Hickey et al. 1996), no data are 
yet available on the in vitro action of those compounds in swine. Analysis of the direct 
effects of GHS on porcine somatotropes appears as a required step to better understand the 
possible role of these secretagogues on the regulation of GH in this species. The knowledge 
of the mechanisms by which ghrelin and other specific GHS stimulate GH secretion may 
ultimately be applied to production of high quality meat. Pork is an important U.S. 
agricultural commodity and a major protein source worldwide. Administration of ghrelin has 
been shown to stimulate pituitary GH secretion, but also increase body growth appetite and 
fat deposition (Wang et al. 2002). The optimization of GH secretion in pigs would be 
expected to increase growth rate and improve the quality of the meat by reducing adipose 
tissue. This further would improve human nutrition and reduce consumption of fat, 
particularly saturated fat - a cause for concern relative to cardiovascular disease and obesity 
in the US population. One primary objective of this thesis is to increase our understanding of 
cellular mechanisms of action of GHS in pigs. In order to ascertain the direct actions of GHS 
and ghrelin on porcine somatotropes we have evaluated their effects on GH release and 
intracellular calcium concentration from cultured pituitary cells. 
Rapid growth in the young pigs requires an episodic pattern of GH secretion. In in 
vivo experiments of Hickey et al. (1996), L-585 had direct stimulatory effect on the pituitary 
gland, but an intact stalk connecting the pituitary and hypothalamus was necessary for 
maximal GH response. The studies included in this thesis focused on determining the 
mechanism of GHS action at he pituitary level. Perfusion application of L-585 had direct 
stimulatory effect on [Ca2+]; in cultured porcine somatotropes. From this study one of the 
most important findings was an increase in [Ca2+]; in cultured somatotropes evoked by L-585, 
coincides with GH release. The experiments with concurrent measurements of calcium 
transient and RHP A have demonstrated that hemolytic plaques were formed only around 
cells that responded with increase in [Ca2+]j to L-585 application, confirming that those cells 
release GH. The stimulatory effect of L-585 on GH secretion from cultured porcine 
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somatotropes was quantified with RHPA. Size and number of plaques were increased in 
somatotropes exposed to L-585 comparing to cells in the resting state, showing that GH 
release from somatotropes is increased after exposure to L-585. In calcium imaging 
experiments it was demonstrated that increase in [Ca2+]; evoked by L-585 application is grater 
than after application hGHRH, implying that L-585 is more potent than hGHRH in the rapid 
release of GH. In vivo experiments in pigs have shown that L-585 is indeed more efficacious 
than GHRH in releasing circulating GH (Hickey et al. 1996). 
It is well documented that GHS and GHRH act through different receptors on the 
somatotropes plasma membrane (Wu et al. 1996). In cultured porcine somatotropes 
stimulatory effects of hGHRH and L-585 on [Ca2+]; were also mediated through different 
receptors. When hGHRH and L-585 were applied in succession, there was no heterologous 
desensitization, while homologous desensitization occurred after repeated application of 
ligands. In addition, SP analogue blocked and GHRH receptor antagonist decreased the 
stimulatory effect of hGHRH, while these treatments did not have influence on the calcium 
transient evoked by L-585. In vivo experiments with pigs have shown that L-585 synergies 
with GHRH (Hickey et al. 1996), but in the present in vitro study hGHRH and L-585 
exhibited no additive effect on intracellular calcium concentration. This is in correlation with 
previous studies where GHS also exerted a synergistic action with GHRH in vivo, while in 
vitro merely exhibited additive activity (Smith et al. 1997). It was shown that GH-releasing 
activity of GHS is clearly higher when hypothalamic pituitary axis is intact (Pombo et al. 
1995, Popovic et al. 1995, Hickey et al 1996). These data and finding that the GH response 
to direct intracerebroventricular GHRP injection was greater than that observed after 
systemic administration of the same dose (Fairhall et al. 1995), point to an important 
hypothalamic action of GHS. 
Somatostatin at a concentration of 10 (iM abolished the effect of both hGHRH and L-
585, whereas 5 jxM SS was more effective in suppressing the stimulatory effect of hGHRH. 
GHS depolarize the plasma membrane of somatotropes by inhibiting K+ channels, and can act 
as a functional antagonist of somatostatin that causes somatotropes hyperpolarization (Smith 
et al. 1993, 1997). This functional antagonism between GHS and SS can explain while lower 
doze of SS did not abolish effect of L-585. 
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Our results suggest that both extracellular and intracellular calcium are involved in 
stimulatory effect of L-585 on cultured porcine somatotropes. The depletion of extracellular 
calcium greatly diminished the stimulatory effect of L-585 suggesting that Ca2+ influx has a 
major contribution in the action of L-585. T- and L-types voltage-gated Ca2+ channels are 
present on somatotropes membrane (Chen et al. 1990). Pretreatment of cultured porcine 
pituitary cells with nifedipine significantly decreased the effect of L-585, indicating an 
involvement of L-type Ca2+ channels in calcium influx induced by L-585. In zero sodium 
HEPES stimulatory effect of L-585 was greatly attenuated, suggesting that L-585 can 
depolarize somatotropes membrane by acting on sodium channels. It is possible that K+ 
channels are also involved in somatotropes depolarization since electrophysiology studies 
showed that peptidomimetics blocked K+ currents in somatotropes that lead to depolarization 
and Ca2+ entry through voltage gated channels (Smith et al. 1997). Pretreatment of cultures 
with low calcium HEPES, nifedipine and zero sodium HEPES, almost abolished the second, 
sustained phase of calcium transient induced by L-585. These results implied that plateau 
phase of calcium transient evoked by L-585 is result of calcium influx, while the first initial 
increase in [Ca2+]; is result of intracellular Ca2+ mobilization. In isolated rat somatotropes 
GHRP-6 evoked a transient increase in [Ca2+];, followed by second long-lasting phase 
(Herrington & Hille 1994). The first phase was due to calcium release, because a Ca2+ 
channel blocker did not block it, and the second phase was due to calcium influx. It is 
proposed that GHRPs first mobilize intracellular Ca2+ and then Ca2+ influx, as a result of 
membrane depolarization and the action of second messengers on Ca2+ channel proteins 
(Chen et al. 1996). We obtained a similar response with L-585 on cultured porcine pituitary 
cells, suggesting a similar mechanism of action between peptidomimetics and L-585. This 
agrees with the finding that peptidomimetics and nonpeptidyl GH secretagogues bind to the 
same receptors on somatotropes (Smith et al. 1997). 
Results from our experiments where the stimulatory effects of GHRH and L-585 were 
decreased with SQ, an AC inhibitor, suggest that action of both ligands is mediated through 
cAMP/PKA pathway. It is well established that GHRH activates the cAMP/PKA pathway in 
somatotropes (Harwood et al. 1984, Frohman et al. 1992), and that part of the effect of S S is 
via its inhibition on cAMP formation (Schonbrunn 1990). The activation of AC by GHS is 
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controversial. It was observed that GHRP-6 and GHRP-1 did not have direct effect on 
intracellular cAMP levels in rat and ovine somatotropes (Cheng et al. 1989, Akman et al. 
1993, Wu et al. 1996). GHRP- 2 increased intracellular cAMP levels in ovine somatotropes, 
but not in rat somatotropes, suggesting the existence of several subtypes of GHS-R that are 
differentially expressed in different species (Wu et al. 1996, Chen 2000). It seems that L-585 
in porcine somatotropes acts on the same subtype of GHS-R that is involved in action of 
GHRP-2 in ovine somatotropes, because our results indicated the involvement of a AC 
signaling pathway in the L-585 action on cultured porcine somatotropes. 
Results from our study suggest that the action of GHRH and L-585, is also mediated 
through PLC pathways. The stimulatory effects of hGHRH and L-585 on calcium transient in 
porcine somatotropes were decreased by pretreatment of cultures with U73122, a PLC 
inhibitor. Previously, it was suggested that action of GHRP and a non-peptidergic analogue 
on GH release is mainly mediated by PLC pathway (Cheng et al. 1991, 1993). This pathway 
produces both IP3, which leads to release of Ca2+ from intracellular stores, and diacylglicerol 
(DAG), which activates PKC. Consistent with activation of PLC pathway were finding that 
GHRP-6 and non-peptidergic GHS increased phosphatidylinositol (PI) turnover, and caused 
translocation of PKC (Adams et al. 1995, Mau et al. 1995). The cells in our study, whose 
response to GHRH was decreased in the presence of U73122, probably were LD cells. Low-
(LD) and high-density (HD) cells are two morphologically and functionally distinct 
somatotrope subpopulations described in rats and pigs (Lindstrom & Savendahl 1996, 
Ramirez et al. 1998, 1999). It was shown that GHRH activated AC in both LD and HD 
subpopulation of porcine somatotropes, whereas GHRH activated PLC pathway only in LD 
cells (Ramirez et al. 1999). 
In the past five years, Dr. Jena and his group focused their studies on the molecular 
mechanism of secretory fusion vesicle. Atomic force microscopy (AFM) in combination with 
electron microscopy, confocal microscopy, electrophysiology, and molecular and 
biochemical approaches has been applied to study the molecular mechanism of membrane 
fusion (Schneider et al. 1997, Jena et al. 1997, Jeong et al. 1999, Cho et al. 2002a,b). The 
AFM is a useful technique for imaging the surface of living cells in three dimensions. The 
surface of the sample is scanning with pyramidal silicon or silicone nitride tip mounted on a 
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cantilever spring and deflection of the tip is detected by laser photometry. With AFM studies, 
new insights have been gained on the structure-function relationships of whole cells, 
subcellular organelles and macromolecules. According to the commonly accepted theory, the 
final step in exocytosis is the total incorporation of secretory vesicle membrane at the cell 
plasma membrane that is later followed by compensatory retrieval of excess membrane by 
endocytosis. However, studies using electron microscopy demonstrate that following 
stimulation of secretion there is no loss of secretory vesicles following exocytosis, but 
depletion of vesicular content results in the formation of empty or partially empty vesicles 
(Lawson et al. 1975, Cho et al. 2002b). In addition, earlier electrophysiological 
measurements on live secretory cells suggested the presence of fusion pores at the plasma 
membrane where secretory vesicles fuse to release vesicular contents (Alvarez de Toledo et 
al. 1993, Monck et al. 1995). Recent studies using AFM demonstrate for the first time the 
presence of the fusion pore involved in exocytosis in live pancreatic acinar and chromaffin 
cells (Schneider et al. 1997, Cho et al. 2002b,c, Lee et al. 2002). These studies have shown 
that "pits" and "depressions" are sites at the apical plasma membrane in live cells, where 
membrane-bound secretory vesicles transiently dock and fuse to release vesicular contents. 
Fusion pores located at the apical plasma membrane of pancreatic acinar cells dilate only 25-
35 % during exocytosis, showing that there is no total incorporation of secretory vesicles at 
the fusion pore which would distend the structure much more then what is observed 
(Schneider et al. 1997, Cho et al. 2002b,d, Lee et al. 2002). These earlier results prompted 
the current study to determine secretory vesicle dynamics in live GH-secreting cells. First, 
the stimulatory effect of L-585 on GH secretion from isolated porcine somatotropes was 
confirmed by RHP A. Surface of plaque around somatotropes stimulated by L-585 was 
increased, comparing to plaque in resting somatotropes, showing an increase in GH secretion 
in stimulated cells. Further, plasma membrane of live and fixed GH secreting cells were 
imaged using AFM, and there was no detectable changes following fixation. Specific plasma 
membrane structures 'pits' and 'depressions' are present at resting somatotropes. After cell 
exposure to L-585 40 % increase in the size of 'depressions' was observed, suggesting 
involvement of these structures in hormone release. This was further confirmed by binding 
gold-tagged GH antibody to the 'pit' structures in the L-585 stimulated cells. This study for 
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the first time documented presence of 'pits' and 'depressions' on neuroendocrine cells, 
suggesting that these structures may be common for all secretory cells. 
Perfusion of isolated porcine somatotropes with an endogenous ligand for GHS-R -
ghrelin also evoked doze dependent increase in [Ca2+]; followed by sustained decline above 
base line. 1 pM ghrelin increased [Ca2+]; in 98 % cells that first responded to the hGHRH. 
Application of ghrelin evoked a similar increase in [Ca2+]; as a 10 x greater concentration of 
hGHRH, suggesting that ghrelin is more effective. Similarly, in humans iv administration of 
ghrelin induced prompt increase in circulating GH levels that was clearly higher than the 
observed after GHRH administration (Takaya et al. 2000, Arvat et al. 2001). There was no 
heterologous desensitization between hGHRH and ghrelin, but homologous desensitization 
occurred after repeated ghrelin application. Previous studies on rat somatotropes have shown 
that serial ghrelin stimulation at 1 h intervals strongly desensitized somatotropes (Yamazaki 
et al. 2002). In agreement with our results from experiments with L-585, simultaneous 
application of hGHRH and ghrelin did not have an additive effect on intracellular calcium 
concentration in cultured porcine somatotropes. It was previously shown in vivo studies in 
humans that ghrelinsynergized with GHRH (Arvat et al. 2001, Hataya et al. 2001), while in 
in vitro studies in rats simultaneous application of these two agents did not elicit either a 
synergistic or an additive GH response (Yamazaki et al. 2002). The similar results were 
obtained in studies with exogenous GHS suggesting that hypothalamus is important sight of 
action of both endogenous and exogenous GHS and that for their maximal effect an intact 
hypothalamo-pituitary axis is necessary. 
The stimulatory effect of ghrelin on porcine somatotropes was mediated by the GHS-
R. In the presence of a putative competitive GHS-R antagonist, (D-Lys3)-GHRP-6, the 
stimulatory effect of ghrelin was considerably decreased, but not abolished. In a stable CHO 
cell line expressing rat GHS-R, the [Ca2+]; increase evoked by small doze of ghrelin was 
depressed in the presence of 10"4 M [D-lys-3]-GHRP-6, but a high doze of ghrelin increased 
[Ca2+]; to the level observed in the absence of the antagonist (Kojima et al. 1999). This 
indicated that ghrelin is competitively inhibited by the antagonist. 
In the presence of S S and NPY, increase in [Ca2+]j evoked by ghrelin was 
significantly smaller. The inhibitory effect of SS can be mediated by decreased cAMP 
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formation (Chen et al. 1996), or by decreased Ca2+ influx as a result of an increase in K+ 
conductance and hyperpolarization of somatotropes (Lussier et al. 1991). Although SS 
inhibits the stimulatory effect of GHS on GH secretion from pituitary (Badger et al. 1984, 
Bowers et al. 1984, Akman et al. 1993), there is evidence suggesting that GHS could act by 
antagonizing the inhibitory activity of S S on GH release by counteracting its hyperpolarizing 
effect on somatotrope cell membrane (Goth et al. 1992, Smith et al. 1997). NPY also exerts a 
negative influence on GH secretion possibly through either stimulating SS neurons or 
inhibiting GHRH neurons (Kamegai et al. 1998). It was shown that NPY releases SS from 
median eminence fragments in vitro (Rettori et al. 1990). NPY neurons express Fos in 
response to GH and NPY neurons in the arcuate express GH receptors suggesting that NPY 
neurons play a physiological role in regulation of GH secretion (Chan et al. 1996). In the 
present study we have demonstrated an inhibitory effect of NPY on ghrelin induce increase in 
[Ca2+]j in somatotropes. The inhibitory effect of NPY at pituitary level was previously 
observed with human somatotropic tumors where NPY reduced GHRH stimulatory effect 
(Adams et al. 1987). In our experiments NPY decreased basal [Ca2+]; implying that NPY can 
reduces stimulatory effect of GHRH and/or GHS by affecting [Ca2+]j. To reveal the exact role 
of ghrelin in GH secretion, future studies should focus on the interactions between ghrelin 
and GHRH, as well as SS, NPY, GH and IGF-I. 
Endogenous ligand for GHS-R - ghrelin and nonpeptidyl GHS - L585 produced very 
similar calcium transient in isolated porcine somatotropes suggesting similar mechanism of 
action. In low calcium HEPES, in nifedipine or in zero sodium HEPES, the second sustained 
phase of calcium transient induced by ghrelin was almost completely abolished. These results 
indicate that the first phase of ghrelin-evoked calcium increase resulted from intracellular 
Ca2+ mobilization, whereas the second phase was consequence of membrane depolarization 
and calcium influx through voltage dependent calcium channels. Experiments with SQ, an 
AC inhibitor, and U73122, a PLC inhibitor, have shown that ghrelin mobilized Ca2+ from 
intracellular stores through activation of AC and PLC pathways. We have drawn the same 
conclusions from studies examining the ability of L-585 to affect [Ca2+]j in porcine 
somatotropes implying that ghrelin and L-585 indeed possess similar mechanisms of action. 
The similar action of ghrelin and peptidyl GHS has been previously shown (Arvat et al. 
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2001, Bowers 2001), but in the present study, we have for the first time shown a similar 
action between ghrelin and the nonpeptidyl GHS, L-585. 
It is proposed that in somatotropes at least two functional receptors for GHRP exist, 
GHRP-R1 and GHRP-R2. Binding of GHRP to those different receptors can activate both 
adenylyl cyclase and phospholipase C, and Gs and Gq are most likely involved in the response 
(Koch et al. 1988). In our porcine pituitary cell cultures, L-585 and ghrelin activated these 
signal transduction pathways, AC and PLC, therefore they also may act through different 
types of receptors that are coupled to Gs and Gq (Fig.l). Furthermore, it is possible that cross 
talk between different signal transduction pathways exists. It was previously demonstrated 
that GHRP-2 activate PKC and cAMP/PKA pathways in ovine somatotropes and it was 
proposed that activation of PKC could potentiate the PKA pathway by increasing activity of 
AC, by enhancing the ability of cAMP to activate PKA or by increasing the size of the 
readily releasable pool of GH (Chen 2000). In many endocrine cells, such as pancreatic (3-
cells (Tamagawa et al. 1985), these two signal transduction pathways frequently act in 
concert to induce hormone secretion. It is reasonable to assume that various combinations of 
the two signaling systems may cooperate and intensify GH secretion from somatotropes. 
Activation of these different signal transduction pathways result with calcium mobilization 
from internal stores during the first phase of L-585 and ghrelin induced increase in [Ca2+];. 
This initial increase in [Ca2+]; is followed by second prolonged phase due to calcium influx, 
that results from somatotrope depolarization by acting on Na+ and K+ channels and the 
activation of calcium channels by acting on different second messengers. 
Experiments where ghrelin and L-585 were applied in succession or simultaneously 
have indicated antagonistic effects between these two agonistes. Application of L-585 10 min 
after ghrelin did not have additive effect on [Ca2+];. In addition, the response evoked by L-
585 was greatly attenuated when applied in the presence of small doze of ghrelin, that alone 
did not have any effect on [Ca2+];. When ghrelin was applied 10 min after L-585 instead of an 
increase, an abrupt decrease in [Ca2+]j occurred. These antagonistic effects between ghrelin 
and L-585 may be result of competition for binding site at GHS-R on somatotropes, which 
may involve different subtypes of GHS-R (Chen 2000). It is also possible that competition 
between ghrelin and L-585 may occur downstream from the GHS-R or sub-types. 
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Figure 1 The proposed signalling pathways for ghrelin and GHS in porcine somatotropes. 
The binding of ghrelin and GHS to a GHS-R activates the PLC and AC pathways via 
different G-proteins leading to an increase in IP3 and and the activity of PKC and PKA. IP3 
than releases Ca2+ from the IP3-sensitive Ca2+ stores and protein kinases phosphorylate ion 
channels. This events together result with increase in [Ca2+]j and GH secretion (modified 
from Chen et al. 1996). 
In summary, L-585 and ghrelin have a direct, dose dependent stimulatory effect on 
porcine somatotropes. Calcium is mobilized from internal stores during the first phase of 
calcium transient evoked by ghrelin and GHS, whereas a second prolonged phase results 
from calcium influx through an increase in cell membrane Ca2+ permeability. The latter is 
reflecting membrane depolarization and action of second messengers on Ca2+ channels. 
Ghrelin and L-585 exerted an antagonistic effect on calcium transients in porcine 
somatotropes, but the exact basis for these actions is unknown. The full elucidation of the 
mechanisms by which ghrelin and other specific GHS stimulate GH secretion would gain a 
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greater insight into our understanding of the mechanisms involved in the regulation of GH 
secretion and somatic growth. This knowledge may ultimately be applied to production of 
high quality meat by optimizing GH secretion using pharmaceutical manipulations, or by 
management, nutrition and/or breeding/genetics. In addition, the knowledge of cellular 
mechanism of GHS action opens up possibility of clinical use to improve diagnosis and 
treatment of different disease states associated with altered GH secretion such as GH 
deficiency, aging, obesity, osteoporosis or cardiovascular diseases. 
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APPENDIX A. GLOSSARY OF TERMS 
AC - adenylyl cyclase 
ACTH - adrenocorticotropin hormone 
AFM - atomic force microscopy 
AGRP - agouti-related protein 
ANOVA - one-way analysis of variance 
AP - anterior pituitary 
ARC - hypothalamic arcuate nucleus 
BSA - bovine serum albumin 
Ca2+ - calcium 
[Ca2+]j - intracellular calcium concentration 
A[Ca2+]; - changes in intracellular calcium concentration 
cAMP - cyclic adenosine monophosphate 
CART - cocaine and amphetamine-regulated transcript 
CHO - Chinese hamster ovary 
CNS - central nervous system 
DAG - l-Oleoyl-2-acetyl-sn-glycerol 
DMEM - Dulbecco's modified Eagle's medium 
BBSS - Earle's balanced salt solution 
EGTA - ethyleneglycol-bis-(P-aminoethyl ether) N,N,N',N'-tetraacetic acid 
FBS - fetal bovine serum 
GH - growth hormone 
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GHRH - growth hormone releasing hormone 
hGHRH - human growth hormone releasing hormone 
GHRP- growth hormone releasing peptides 
GHS - growth hormone secretagogues 
GHS R - growth hormone secretagogues receptor 
HD - high density 
HEPES - (N-[2-Hydroxyethyl]piperazine-N"-[2-ethanesulfonic acid]) 
HS - horse serum 
ICC - immunocytochemistry 
icv - intracerebroventricular 
IGF-I - insulin-like growth factor I 
IP3- inositol 1,4,5-trisphosphate 
iv - intravenous 
K+ - potassium 
L-692,585-L-585 
LD - low density 
MEM - minimum essential medium 
MP A - the mean plaque area 
Na+- sodium 
NEF A - nonesterified fatty acids 
f 
NPY - neuropeptide Y 
NSF - N-ethylmaleimide-sensitive fusion protein 
PBS - phosphate buffer saline 
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PFC - plaque forming cells 
PI - phosphatidylinositol 
PKA - protein kinase A 
PKC - protein kinase C 
PLC - phospholipase C 
POMC - proopiomelanocortin 
PRL - prolactin 
PVN - hypothalamic periventricular nucleus 
RHP A - reverse hemolytic plaque assay 
S.E. - standard error 
S.E.M. - standard error of mean 
SNAPs - soluble N-ethylmaleimide-sensitive fusion protein attachment proteins 
SNAREs - SNAP receptors 
SP - substance P 
SS; SRIH - somatostatin 
TM - transmembrane 
TSI - total secretion index 
VMN - hypothalamic ventromedial nucleus 
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